UC Irvine

UC Irvine Previously Published Works

Title

Retinoic acid signaling and neuronal differentiation.

Permalink

<https://escholarship.org/uc/item/1zr3w1tc>

Journal

Cellular and molecular life sciences : CMLS, 72(8)

ISSN

1420-682X

Authors

Janesick, Amanda
Wu, Stephanie Cherie
Blumberg, Bruce

Publication Date

2015-04-01

DOI

10.1007/s00018-014-1815-9

Copyright Information

This work is made available under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives License, available at
<https://creativecommons.org/licenses/by-nc-nd/4.0/>

Peer reviewed

Retinoic acid signaling and neuronal differentiation

Amanda Janesick · Stephanie Cherie Wu ·
Bruce Blumberg

Received: 23 October 2014 / Revised: 15 December 2014 / Accepted: 19 December 2014 / Published online: 6 January 2015
© Springer Basel 2015

Abstract The identification of neurological symptoms caused by vitamin A deficiency pointed to a critical, early developmental role of vitamin A and its metabolite, retinoic acid (RA). The ability of RA to induce post-mitotic, neural phenotypes in various stem cells, *in vitro*, served as early evidence that RA is involved in the switch between proliferation and differentiation. *In vivo* studies have expanded this “opposing signal” model, and the number of primary neurons an embryo develops is now known to depend critically on the levels and spatial distribution of RA. The proneural and neurogenic transcription factors that control the exit of neural progenitors from the cell cycle and allow primary neurons to develop are partly elucidated, but the downstream effectors of RA receptor (RAR) signaling (many of which are putative cell cycle regulators) remain largely unidentified. The molecular mechanisms underlying RA-induced primary neurogenesis in anamniote embryos are starting to be revealed; however, these data have not been extended to amniote embryos. There is growing evidence that bona fide RARs are found in some mollusks and other invertebrates, but little is known about their necessity or functions in neurogenesis. One normal function of RA is to regulate the cell cycle to halt proliferation, and loss of RA signaling is associated with dedifferentiation and the development of cancer. Identifying the genes and pathways that mediate

cell cycle exit downstream of RA will be critical for our understanding of how to target tumor differentiation. Overall, elucidating the molecular details of RAR-regulated neurogenesis will be decisive for developing and understanding neural proliferation–differentiation switches throughout development.

Keywords Neurogenesis · Retinoic acid receptor · Proliferation-differentiation switch

Introduction

The role of retinoic acid (RA) in neurogenesis has been known indirectly for as long as halibut (halibut) and cod liver oils were used to remedy neurological and ophthalmic disorders. Vitamin A, from which RA is derived, was discovered to be fat-soluble in 1891, labeled as vitamin A in 1920, chemically described in 1931, and synthesized in 1946 (reviewed in [1]). Prior to receiving its name, vitamin A had been known for years to be essential to life—the ancient Egyptians used extracts of (vitamin A rich) beef liver to treat night blindness more than 3,500 years ago and the Greeks prescribed the eating of liver to cure night blindness since at least 300 BC [2]. The link between vitamin A and vision was firmly established in the 1930s when George Wald identified vitamin A in the retinas and melanin-containing choroid layers of eye [3]. “Pigs born without eyeballs” was the title of one researcher’s report about a pregnant gilt (young female pig) that received a vitamin A-deficient (VAD) diet and gave birth to 11 piglets without eyes [4]. The etymology of *retin*-ol, -al, -oic, -oid was derived from the retina, where these molecules were first discovered [5].

The first VAD animals possessed many other neuropathies in addition to blindness. Early studies found spinal

A. Janesick · S. C. Wu · B. Blumberg (✉)
Department of Developmental and Cell Biology,
2011 Biological Sciences 3, University of California,
Irvine 92697-2300, USA
e-mail: Blumberg@uci.edu

B. Blumberg
Department of Pharmaceutical Sciences,
University of California, Irvine, USA

cord abnormalities in swine fed a diet consisting nearly entirely of wheat [6]. Although the authors noted that the abnormalities disappeared when the diet was supplemented with “Fat soluble A” (later identified as vitamin A), they attributed neural degeneration to wheat toxicity rather than a dietary deficiency [6]. A more definitive study was later conducted in pigs fed an otherwise nutritious diet that was solely deficient in vitamin A [7]. Nerve degeneration was found in the spinal cord, optic, femoral, and sciatic nerves, as well as the lateral geniculate body [7]. A severe neuromuscular phenotype, complete with hind limb paralysis, was observed in rats deprived of vitamin A prenatally, whereas only partial paralysis was seen in rats deprived of vitamin A postnatally [8]. Indeed, replicating paralysis in other animal systems proved difficult since vitamin A is readily stored in the fetus [8]. Therefore, historical examples of neurological symptoms from VAD pointed to a critical, early developmental role of vitamin A, and by association, RA.

In the early 1980s, it was discovered that RA induced multipotent P19 embryonal carcinoma cells to differentiate into neuronal and glial tissue, *in vitro* [9]. F9 embryonal carcinoma cells differentiated into neurons with the addition of RA and dibutyryl cAMP [10]. The ability of RA to induce neural phenotypes on various stem cells *in vitro* is summarized in [11]. Shortly after the cloning of the first retinoic acid receptors (RARs) [12, 13], it was observed that the P19-derived cell line, RAC65, was incapable of neuronal differentiation due to a 70-amino acid truncation in the RAR α ligand-binding domain [14, 15]. Since DNA-binding was still intact, but activation by ligand was inhibited, the receptor acted as a dominant transcriptional repressor, aka, a dominant negative (DN) receptor. Further investigation showed that the RAC65 line was also unable to up-regulate p27^{Kip1}, a negative cell cycle regulator, and key effector of RA-mediated inhibition of cell cancer growth [16, 17]. These studies demonstrate that RAR α is an essential factor in neuronal differentiation, *in vitro*, and links RA signaling to the cell cycle and a proliferation–differentiation switch.

Studies from several groups showed that both the number of primary neurons an embryo develops and the time that those neurons appear depends critically on the level of RA signaling [18–21]. Whole mount *in situ* hybridization studies revealed that both RAR α and RAR γ are localized in the neural plate and neural tube in neurula-stage embryos; hence, the receptors are expressed at the correct time and place to regulate primary neurogenesis [22]. DN-RAR α injected embryos lacked primary neurons and were paralyzed and unresponsive to touch; microinjection of the constitutively active VP16-RAR α , or xRXR β together with xRAR α 2 created ectopic neurons [19, 21]. Reduced RA signaling in VAD quail led to a paucity of neurons in the spinal cord, concurrent with loss of

proneural genes, such as *Neurogenin1/2* [23, 24]. Increasing RA levels in chick spinal cord explants resulted in increased expression of *NeuroD*, a basic helix–loop–helix protein that promotes neural differentiation [23]. Treatment of *Xenopus* embryos with RA or the RAR-selective agonist TTNPB led to ectopic primary neuron formation in the neural plate; antagonist treatment, or loss of either RAR α or RAR γ led to the loss of primary neurons and subsequent paralysis of embryos [22].

In this review, we discuss neurogenesis primarily in terms of how RA facilitates differentiation of neurons at the expense of proliferation. We explore the evolution and mechanism of RARs in neurogenesis and identify key molecular cell cycle regulators of neuronal development as well as potential downstream effectors of RAR signaling. Finally, we propose how cancer differentiation therapy can benefit from knowledge of RA and proliferation–differentiation switches.

Neurogenesis as a model to study proliferation–differentiation switches

Developing systems exhibit a dynamic balance between cell proliferation and differentiation. The molecular mechanisms regulating this equilibrium remain an important, yet poorly understood question in development. The opposing signal model is a significant conceptual advance in developmental patterning [23]. In its most general terms, the model holds that mutually inhibitory interactions between factors promoting proliferation, and those promoting differentiation, regulate developmental patterning processes. For example, fibroblast growth factors (FGFs) promote proliferation while largely inhibiting differentiation; RA is a differentiation-inducing molecule that inhibits cell proliferation. Examples of RA mediating proliferation–differentiation switches occur frequently in developmental biology. RA-regulated processes include somitogenesis and axial elongation, cardiogenesis, neurogenesis (e.g., primary neurogenesis, hindbrain patterning, eye morphogenesis), limb development, and visceral organ formation [23, 25–28]. Regulating the switch between proliferation and differentiation is fundamental to vertebrate neurogenesis.

Vertebrate neural induction requires inhibition of bone morphogenetic protein (BMP) signaling [29]. FGFs and other growth factors play important, but incompletely understood roles in facilitating neural induction or A-P patterning (reviewed in [30]). Neural induction is associated with the expression of a suite of pro-proliferation transcription factors, downstream of FGF signaling (*Foxd411* and *Zic3*) or BMP inhibition (*Zic1*) [29, 31–36] (Fig. 1). *Zic1* and *Zic3* stabilize the neural fate immediately after neural induction, promoting proliferation of neural progenitors, up-regulating Notch signaling, and inhibiting

Fig. 1 Important proliferation factors that mediate the early transcriptional response of BMP inhibition and FGF signaling downstream of neural induction. After neural tissue is induced through active FGF and Ca^{2+} signaling and BMP inhibition, *Zic1*, *Zic3* and *Foxd4l1* are up-regulated [29, 34–36, 48, 49]. *Foxd4l1* and *Zic3* are downstream targets of FGF signaling, possibly mediated by AP-1 [32–34, 263, 264], whereas *Zic1* is an immediate early gene of BMP inhibition and is driven by a BMP inhibitor-responsive promoter module (BIRM) [34, 35]. *Geminin* (Gem) and *Zic2* are regulated by *Foxd4l1* and promote *Notch* signaling and inhibition of proneural gene *Neurogenin* [31, 52–55]. *Zic1* also promotes *Notch* signaling and directly represses proneural gene *Math1* [40, 41]. Cross-regulation between *Geminin*, *Zic*, *SoxB1* (*Sox2* and *Sox3*), *Sox11*, and *Notch* maintains proliferation in the neuroectoderm [39, 50, 54–56]. Potential inhibitory interactions between *Sox11* and *Zic* genes are explored in Moody 2013, but not displayed here. Collectively, proneural genes *Neurogenin* and *Math1* are repressed by these proliferative signals, and primary neurogenesis is inhibited as a result. RA inhibits neural proliferation quite early in this process by downregulating the expression of *Geminin*, *Zic1/2/3*, and *Notch* [22]

differentiation [37–41]. *Zic3* is a direct target of the pluripotency factors *Oct4*, *Nanog*, and *Sox2* [42–44], and its expression is diminished after differentiation with RA [43]. Calcium signaling through L-type calcium channels is also a major player in neural induction and is required for the expression of *Zic3* and *Geminin* [45–49]. *Geminin*, a gene that postpones lineage commitment of cells [50], is associated with proliferating neural progenitors [51] and interacts with *Brahma-related gene 1* (*Brg1*) to inhibit neuronal differentiation [52]. *Zic2* is downstream of *Foxd4l1* and is expressed in an alternating pattern with *Neurogenin*; *Zic2* inhibits *Neurogenin*, and therefore, neurons do not differentiate where *Zic2* is expressed [53]. *FoxD4L1*, *Geminin*, *Zic1* and *Zic3* promote *Notch*, *Sox2* and *Sox3* expression [39, 50, 54–56]. The concerted action of this group of genes promotes proliferation and maintenance of immature neural precursors (Fig. 1).

Through an as yet unclear mechanism, neural progenitors exit from the cell cycle and differentiate into primary neurons under the control of the proneural and neurogenic transcription factors such as *Neurogenin*, *Math1*, *Ascl2*, *MyT1* (Fig. 1) (reviewed in [57, 55]). Primary neurons are defined as four sets of neurons (sensory, interneurons, motor, and trigeminal) visible in the open neural plate stage. Primary neurons differentiate from the deep neuroectoderm layer of the embryo, whereas the superficial neuroectodermal layer maintains an immature, proliferative state [58]. We and others showed that RA is required for primary neurogenesis [19, 21, 59]. RA inhibits the expression of *Zic*, *Geminin*, *Notch*, and *Foxd4l1* while promoting expression of proneural and neurogenic genes [18, 22] (Fig. 1).

Primary neurogenesis in anamniotes versus amniotes

Primary neurogenesis is an important model for understanding proliferation–differentiation switches in all species throughout development; it also describes how the adult brain can regenerate new neurons, and how cancer cells arise. However, primary neurogenesis, per se, only occurs in anamniote embryos, which develop neurons as early as the neural plate stage, later enabling the larvae to swim and feed precociously [60, 61]. Since amniote (reptilian, avian and mammalian) embryos are protected from the external environment and develop completely before hatching, primary neurons are not required for survival and were probably lost during evolution [62]. The earliest born neurons of the cortex are often referred to as secondary neurons in anamniotes, although this process corresponds to primary neurogenesis in amniotes. Terminology aside, it is quite likely that the first cortical neurons in amniotes will be initiated using a mechanism similar to primary neurogenesis in anamniotes.

Before any developmental mechanism can be elucidated, these incipient neurons for amniotes, secondary neurons for anamniotes, must be defined, yet this has remained elusive. Early-born axon tracts, nerve fibers that establish a scaffold for which other axons can follow, are predicted to serve as “pioneer” neurons in the developing brain (reviewed in [63]). Unlike primary neurons, these pioneer neurons exist not for basic survival, but rather, because the embryo is sufficiently small that guidance cues (e.g., chemoattractants) are close enough for axon trajectories to be established [64]. Recent labeling studies in aborted human embryos identified so-called “predecessor neurons” in the preplate, which are the earliest identified neurons to date [65]. Like primary neurons, these “predecessor neurons” are created prior to neural tube closure and are likely to be transient in nature [65]. Whether RA is involved in the differentiation of predecessor neurons from

proliferating neuroepithelial cells is unknown. However, considering that evolution often conserves developmental mechanisms, the possibility is very likely and remains an interesting open question.

Although there is no clear picture on how RA might foster differentiation of the earliest neurons in amniotes, and secondary neurons in anamniotes, RA does play other important, evolutionarily conserved roles in CNS development across most chordates, including three major patterning processes: (1) posteriorization of neuroectoderm; (2) D-V patterning of the spinal cord; (3) A-P patterning of the hindbrain. Excellent reviews have been written about these well-known patterning events [11, 25–27, 66, 67]. Briefly, RA together with Wnts and FGF signaling posteriorizes neuroectoderm, which would otherwise be anterior in character by default [19, 68]. Similarly, RA signaling is an important component of the neural posteriorizing pathway in the hindbrain—RA determines the identity and delineates borders of posterior rhombomeric segments (reviewed in [69]). During neurulation, RA secreted from paraxial mesoderm functions in the specification of nerve cell types in the spinal cord, in particular, motor neurons ([70], reviewed in [67]).

Most examples in amniotic systems concern the function of RA in patterning neural tissue—there is a paucity of information about how RA promotes neuronal differentiation. We consider three areas where RA plays a role in differentiation: in photoreceptors, hippocampus, and cortical neurons. RA can cause dissociated, neonatal rat retinas in culture to differentiate into photoreceptor cells expressing *rhodopsin* and/or *recoverin* [71]. Human, mouse, and monkey embryonic stem cells can also be differentiated into rod photoreceptors, albeit more laboriously, due to the requirement of an intermediate step of *Notch* inactivation, followed by a cocktail containing RA, Shh, FGFs, and taurine [72]. This suggests that RA is more important in the final steps of rod photoreceptor differentiation than in the early process of differentiating ES cells into retinal progenitors. In contrast, both mature (NeuN⁺) and immature (dcx⁺) neurons of the hippocampal dentate gyrus are reduced in retinoid-deficient mice, indicating that RA affects very early steps of the neuronal differentiation pathway in the hippocampus [73]. Neural stem cells in the proliferative ventricular zone of the cortex also require RA to differentiate into intermediate progenitor cells of the sub-ventricular zone and post-mitotic neurons of the cortical plate [74]. Meninges are thought to be the source of RA due to high levels of RA-synthesis enzymes, ALDH1A2 and RDH10 [74, 75]. *Foxc1* mutant mice that fail to form meninges normally exhibit increased proliferation, and are deficient in mature, Ctip2⁺ neurons [74]. However, when forebrain explants from *Foxc1* hypomorphs were co-cultured with wild-type meninges (from

which RA diffuses), cell cycle exit was restored [74]. How RA regulates differentiation in other aspects of cortical development, and how these processes can be related to the gene networks observed in vertebrate primary neurogenesis remain to be explored.

What was the first RAR-regulated nervous system?

A neural plate or neural tube need not be present for neurogenesis to occur. For example, the primitive acoelomorph flatworm, *Symsagittifera roscoffensis* (aka the mint sauce worm), which is considered to represent the earliest extant bilaterian organism, lacks a nerve cord, but possesses neurite bundles that span the A-P axis of the body [76]. Prior to the emergence of more complex bilaterians, nerve “cords”, “nets”, and “rings” already existed in cnidarians [77, 78] and ctenophores [79, 80]. Secretory apparatus resembling synaptic vesicles required for neurotransmitter communication can be found in single-celled choanoflagellates [81]. Therefore, it is clear that neural tissue can adopt a variety of forms, yet retain the function of communication between one part of the organism and others. Where then do retinoids fit into this process?

Data from vertebrate embryology support an essential role for retinoid signaling in the development of primary neurons [19, 21, 22, 24]. However, it is equally clear that nervous systems of considerable complexity can be found in organisms for which RARs have not been identified (e.g., *Drosophila melanogaster*). The larvacean urochordate, *Oikopleura dioica* can form a functional nervous system that expresses homologs of marker genes for vertebrate forebrain, hindbrain and spinal cord (but not midbrain) in their CNS [82], yet it lacks important components of RAR signaling (RARs, CYP26), while retaining RXR and Adh3 [83]. Intriguingly, other urochordates, hemichordates, and cephalochordates express RARs and RXRs, as do echinoderms [84, 85]. It is clear that the RA signaling machinery has been lost in *Oikopleura* [85], although, it is not known to what extent their nervous system function is altered compared with other urochordates.

The recent explosion in genome sequences from taxonomically diverse organisms reveals the presence of RARs and RXRs in a variety of invertebrates beyond the deuterostome superphylum. Components of the RAR signaling machinery have been reported from cnidarians, mollusks and nematodes [86] and 9cRA and other RXR activators perturb development in mollusks [87–90]. Uncovering RAR homologs in lower organisms is relatively straightforward in silico, and numerous examples have been identified [86]. A quick BLAST search for this review using the RAR α ligand-binding domain, identified putative

RARs in Pacific oyster, *Crassostrea gigas* and the California sea hare, *Aplysia californica*, among others (Fig. 2). Bioactive retinoids and RARs exist in some Lophotrochozoan species, e.g., the owl limpet, *Lottia gigantea*, the bristleworm, *Capitella telata*, and the giant pond snail, *Lymnaea stagnalis* [86, 91]. *Lymnaea* were shown to contain atRA and 9cRA in the hundreds of nanomolar

range, and treatment with either chemical induced neurite outgrowth and growth cone turning in cell culture [92]. Putative RAR [93, 94] and RXR [87, 95] orthologs were recently cloned in the rock shell, *Reishia clavigera* and dogwhelk, *Nucella lapillus*. Both species of gastropods are susceptible to imposex induced by RXR activators (rexi-noids) [87, 89].

Fig. 2 MAFFT alignment of RAR α 2 in *Homo sapiens* versus Lophotrochozoan species. Alignment begins with the conserved DNA-binding domain of RAR α 2 (no conservation is observed in the N-terminal region)

DNA Binding Domain

Homo sapiens	SPPLPRVYKPCFVCQDKSSGYHYGVSSCEGCKGFFRRSIQKNMVYTCRDKNCIINKVTR
Crassostrea gigas	SPPPPRVYKPCVVCSDKSSGYHYGVSSCEGCKGFFRRSVQKNMQYTCHKDKNCIPINKVTR
Lottia gigantea	SPPPPRVYKPCVVCCLDKSSGYHYGVSSCEGCKGFFRRSVQKNMQYTCHKDKNCIPINKVTR
Aplysia californica	SPPLPRVYKPCVVCNDKSSGYHYGVSSCEGCKGFFRRSVQKNMQYTCHKDKNCIPINKVTR
Lymnaea stagnalis	SPPPPRVYKPCVVCNDKSSGYHYGVSSCEGCKGFFRRSVQKNMQYTCHKDKNCIPINKVTR
Reishia clavigera	S-PPPPRVYKPCVVCNDKSSGYHYGVSSCEGCKGFFRRSVQKNMQYTCHKDQTCPIKINKVTR
Nucella lapillus	SPPPPRVYKPCVVCQDKSSGYHYGVSSCEGCKGFFRRSVQKNMVYTCHEKICIVINKTTR
Capitella telata	* * * * * : * * * * * : * * * * * : * * * * * : * * * * * : * * * * * : * * * * *
Homo sapiens	NRCQYCRLOKCFEVMGSKESVRNDRNKKKKVPEKPECSE-----SYLTPEVGLIELK
Crassostrea gigas	NRCQYCRLOKCYATGMSKEAVRNDNRNKKKKPKLENPSSN-----IEEVTEDEQSVLQE
Lottia gigantea	NRCQYCRLOKCFEVMGSKESVRNDRNKKKKKAAESSSSSSSTTSTSELTTEENMLLQD
Aplysia californica	NRCQYCRLOKCIIMGMSKEAVRNDNRNKKKKQKPESTGL-----SELTEDDQMLIQE
Lymnaea stagnalis	NRCQYCRLOKCVVMGMSKEAVRNDNRNKKKKQKPESTSGG-----PDEVTEDDQMLIQE
Reishia clavigera	NRCQYCRLOKCLAMGMSKEAVRNDNRNKKKKPNKPSS-----VGSVASELTEDDHLLIQE
Nucella lapillus	NRCQYCRLOKCLAMGMSKEAVRNDNRNKKKKLAQMDADSGCGPGGSPPEVELTDDQTLIQD
Capitella telata	NRCQYCRLOKCLATGMSKEAVRNDNRNKKKKKEEGCSSS----TQPQAEELTSEESDLIEC
	****:***** ***:*****:***: . : * : : :
Homo sapiens	VRKAHQETFPALCQ-----LGKYTTNNSS-----EQRVSL
Crassostrea gigas	ILEAHRVTFPQIEEAVLSPMSC-----HTRGD-----IENDEASKENSQKKE
Lottia gigantea	VLEAHLRTYKSPAE-----NGDKENETKNGNK
Aplysia californica	VLDADRDTTPNSQNGATLPFSSATADLVGTTTAAATTPPSKA---TSTSESRSDDSSGSS
Lymnaea stagnalis	VLDADRDTTPDGVNGSTLPGSSSGA---ATSSMAANSSPTVA---TSTSETKSEDD--SGSS
Reishia clavigera	VLEAHRVTSFG-----YDTRANTCTPPQMSPTQET-----VEKGAP
Nucella lapillus	VLEAHRATTPALTNHSSPI-----TTQVEVRSFPDQKGSQ
Capitella telata	ITATHEYTFPLILEDEKIKLSA-----EDIARE
	: : * . *

Ligand Binding Domain

Homo sapiens	DIDLWDKFSELSTKCIKIVTEFAKQPLGFTTLTIADQITLLKAACDLILIRICTRYTPEQ
Crassostrea gigas	KSMWLWDKVELSSKGIKIVTEFAKMPGFTSLSTSDQITLLKAACLEIMILRLCSRYDLK
Lottia gigantea	---LWDKISLSSGGIVKIVDFAKKINGFSSLCSTSDQITLLKAACLEIMILRLSFRYDPL
Aplysia californica	GVFLWEKITELSSAGIVLIVDFAKKIPGFLSLSTSDQITLLKAACLEIMILRISIRYEMDT
Lymnaea stagnalis	GVFLWEKITELSSAGIVMIVDFAKKIPGFLSLSTSDQITLLKAACLEIMILRISIRYELDT
Reishia clavigera	GVFLWEKITELSSAGIVKIVDFAKKVPDFLTITSDQITLLKAACLEIMILRICNCYDMEK
Nucella lapillus	GVFLWEKITELSSAAIVKIVDFAKKIPGFLSLSTSDQITLLKAACLEIMILRICERYSVR
Capitella telata	KVILWERVSELSTSGIVRIVDFGRVPGFQTLSSSDQITLLKSACLEIIVLRLGSRVHEDD
	* * : : * : * : * : * : * : * : * : * : * : * : * : * : * : * : * : * : *
Homo sapiens	DTMTFSDGLTLNRTQMHNAGFGPLTDLVFAFANQLLPLEMDAETGLLSAICLICGRDQDL
Crassostrea gigas	DVMLFNGGLSLDREQLQGGFGTLTDTIFRFASSLKVNLIDEMEYAVLSAICLISGDRSL
Lottia gigantea	DSMVFSNKKVCINREQLLEGGFGVLAATIFNFAASLKSMSTDETEFAVLSAVCLVSGDRSGL
Aplysia californica	DTMQFPGSLALTREQLQGGFGPLTSTIFSFAASLKRMDCEDEYAMLSSICLISGDRSGL
Lymnaea stagnalis	DTMQFNGSLSTREQLQGGFGPLTSTIFSFAASLKRMDCEDEYAMLSSICLISGDRSGL
Reishia clavigera	DMIQFNGSLSRDELQGGFGPLTNTIFSFAASLKRMDCEDEYAMLSSICLISGDRSGL
Nucella lapillus	DMVHFADGTWLRLQEEVEQGGFGPLTAKIFHLARQLHSLRCDQTEFAMLSGVCLISGDRSGL
Capitella telata	ETITFTNGLTLTRQQLLEGGFGTLTDLTILRFAKSLQQMQVDTEYALLSAICLISGDRSGL
	: : * . : : : : * * * : : : * . * : * * : . : * : * : * : * : * : *
Homo sapiens	EQPDRVMDLQEPILLEALKVYVRKRRPSRPHMFPMKMLKITDLRSISAKGAERVITLMEIP
Crassostrea gigas	EESERVEQMQLLEALKHYVRTRRKDQPNVFAKILYKLTDLRSISVKGAEVRLHLRLKMP
Lottia gigantea	KESVKIEQLQEPILLEALKHYVRSRREEQPHVFAMKMLKLTDLRSISVKGAEVRLHLRLKMP
Aplysia californica	QDTEKIEQMQLLEALKHYIRSRRPDQPHIFAKMLMTLTLDRSISVKGAEVRLHLRLKMP
Lymnaea stagnalis	HDTEKIEQMQLLEALKHYIRSRRPDQPHIFAKMLMTLTLDRSISVKGAEVRLHLRLKMP
Reishia clavigera	TDVKKIEQMQLLEALKHYIRSRRPDQPHIFAKMLMTLTLDRSISVKGAEVRLHLRLKMP
Nucella lapillus	EDVDRIEQMQLLEALKHYVRSRRPDQPVFAKMLMTLTLDRSISVKGAEVRLHLRLKMP
Capitella telata	EDPEKVEALQEPILLEALKHYIRRRSSLPHSFAKILMTLTLDRSISVKGAEVRLHLRLKMP
	: : : : * * * : * * * : : * * * : * * * : * * * : * * * : * * * : * * *
Homo sapiens	GSMPLIQELENSEGLDTLSGQPGGGGRDGG-GLAPPPGSCSPSSPSNRSSPATHSP
Crassostrea gigas	DELPLLIEMLDQENLITDSMLSQDQVVGTIENFRVYLEAVGHEHTEKDVCMYMEWKP
Lottia gigantea	GELPLPLVVEMLDRTEVCIP-----
Aplysia californica	APIPLPLVVEMLERVENVCIP-----
Lymnaea stagnalis	AQLPLPLVVEMLERVENVCIP-----
Reishia clavigera	GELSPLVIEMLDRSENVCIP-----
Nucella lapillus	GTLPLPLVIEMLDRVENVCIP-----
Capitella telata	DELPLPLIEMLDRTENVCIP-----
	: . * * : * * : * .

AF-2 Domain

It is important to note that the presence of an apparent RAR or RXR in a particular species does not conclusively show that the receptor will bind to RA and regulate gene expression in an RA-dependent manner. For example, *Reishia clavigera* and *Nucella lapillus* RARs and RXRs heterodimerize as do their vertebrate counterparts, but tcRAR and nLRAR appear not to be responsive to RA [87, 93]. Some investigators have speculated that many invertebrate nuclear receptors could have functions different from than regulating hormonal responses [96], although, others take the opposite position, that hormone-responsiveness was the ancestral state for nuclear receptors [97, 98]. Taken together, the evidence suggests that RA signaling is an ancient process that has been repeatedly lost in a variety of lineages [99]. While important for neural development and differentiation in vertebrates and most chordates, there is a considerable knowledge gap regarding requirements for RA signaling during invertebrate neurogenesis. It is tempting to speculate that advanced cephalopod mollusks with complex nervous systems, such as the octopus, have retained RA signaling in neurogenesis.

Neuronal differentiation and cell cycle genes

Proliferation within neural tissue is a direct consequence of self-renewal via symmetric (giving rise to two daughter stem/progenitor cells) or asymmetric (giving rise to one stem/progenitor cell and one lineage-restricted cell) cell division (reviewed in [100]). There are two schools of thought with respect to how cells make the proliferation–differentiation decision during the cell cycle. In the first, differentiation of neural stem cells is characterized by asymmetrical cell divisions leading initially to fate-restricted progenitors, and finally to terminally differentiated daughter cells that are incapable of dividing (reviewed in [101]). Critically, the proliferation/differentiation decision does not rely on cell cycle arrest, but rather a terminally differentiated cell is simply born in G0 and never makes a decision to proliferate or differentiate (reviewed in [101]). An alternative view is that cell cycle arrest turns a proliferative cell into a post-mitotic cell that differentiates into its final form. A checkpoint towards the end of G1 phase serves as a major restriction point where cells can continue to divide or enter the quiescent G0 phase [102, 103]. Signals favoring neuronal differentiation (e.g., RA) increase the expression of CDK inhibitors which promote cell cycle exit of G1 phase cells [104, 105]. While these two views appear to be mechanistically distinct, they are really quite similar because the genes promoting cell cycle exit and those responsible for stabilizing the G0 phase are identical. Thus, irrespective of whether the terminally differentiated cell was naturally born in G0 or

came to G0 from G1, the molecular factors that got them to G0 are the same.

Chromatin remodeling processes control chromosome assembly and segregation, regulating DNA accessibility throughout the cell cycle by condensing or decondensing DNA, thereby manipulating the inactivation or activation of the replication machinery. Chromatin remodelers are therefore, key determinants in proliferation–differentiation decisions. Brahma-related gene 1 (*Brg1*) is the catalytic subunit that provides ATPase activity to the chromatin remodeling complex SWI/SNF for nucleosome disruption [106]. *Brg1* is required for neuronal differentiation as demonstrated by loss-of-function studies facilitated by morpholino (MO) injection in *Xenopus* embryos [107]. Loss of *Brg1* function leads to an expansion of the neural progenitor population and decreased expression of the neurogenic basic helix–loop–helix (bHLH) genes *Neurogenin* and *NeuroD* as well as the neural differentiation marker *N-Tubulin* [107]. *Brg1* activity is antagonized by *Geminin* which suppresses neurogenesis and inhibits *Neurogenin* and *NeuroD* transcriptional activity [52]. Eyes absent homolog 1 (*Eya1*) and Six homeobox1 (*Six1*) also interact with *Brg1*, recruiting SWI/SNF to mediate the transcription of *Neurog1* and *Neurod1* in the otocyst and cochlea [108]. The role of *Brg1* in mammalian systems is more complex. Conditional deletion of murine *Brg1* led to reduced mitotic index in cultured neural progenitors [109]. However, another study found that deletion of *Brg1* did not alter cell cycle length or cause an increase in proliferation [110]. Rather, *Brg1* controls neuronal fate decisions: neural stem cells derived from *Brg1*-knockout mice differentiate towards the ependymal (glial) lineage, at the expense of the neuronal lineage [110].

Cyclin-dependent kinase inhibitors (CKIs), such as proteins belonging to the Ink4 and Cip/Kip families, inhibit different cyclin-CDK complexes at different time points, and govern cell cycle progression/withdrawal [111–115]. Cip/Kip proteins mediate the assembly of CyclinD-CDK4/6 in early G1 phase [111]. However, in the presence of Ink4, the CyclinD-CDK4/6 complex is disassembled and Cyclin D is targeted for degradation, thus freeing Cip/Kip proteins to bind and inhibit CyclinE-CDK2 [111]. The inhibition of CDK2 by Cip/Kip and CDK4/6 by Ink4 prevents the cell from progressing through the G1-S transition, causing G1 arrest [116, 117]. CKIs play important roles in neurogenesis, influencing cell fate decisions by controlling the timing of onset of neural determination gene expression [118]. In the developing mouse neocortex, ectopic expression of *p27^{Kip1}* was shown to prolong G1 phase [119], a hallmark of cells proceeding to neuronal differentiation [101]. Loss of *p27^{Kip1}* causes increased proliferation in the adult dentate gyrus due to a delay in cell cycle exit of immature neurons. *p27^{xic1}*, a *Xenopus* Cip/Kip

protein, is required for primary neurogenesis [120–122] and functions by CDK inhibition which prevents phosphorylation and promotes stabilization of the Neurogenin protein [120, 123]. Recently, $p27^{xcl}$, was shown to be phosphorylated by atypical protein kinase C (aPKC), which prevents CDK inhibition, shortens the G1 phase of neural progenitors, and encourages their proliferation [124]. The p21-activated serine/threonine protein kinase Pak3 also promotes cell cycle withdrawal and causes premature primary neurogenesis in *Xenopus* [125].

Another aspect of cell cycle control in neurogenesis concerns calcium (Ca^{2+}) influx. Barth and colleagues first identified a role for Ca^{2+} in neural induction by demonstrating that dorsal ectodermal explants could be differentiated into neural cells in the presence of Ca^{2+} and LiCl [126]. Later, it was demonstrated in *Xenopus laevis* and *Pleurodeles waltl* that explants exposed to dissociation medium (Mg^{2+} and Ca^{2+} -free) also differentiated into neural cells [127, 128]. The mere act of dissociation was enough to release Ca^{2+} into the cells [129]. Neuralization of explants could also be induced by Concanavalin A [46, 130, 131], which promotes Ca^{2+} influx/uptake [132, 133], and this was inhibited by Ca^{2+} channel antagonists [46]. However, during normal embryonic development cells are neither dissociated into individual cells nor is Concanavalin A (a legume glycoprotein) an endogenous factor. Hemmati-Brivanlou and Melton proposed the default neural model wherein inhibition of BMP signaling, per se, is necessary and sufficient for neural induction [134, 135]. Subsequent experiments showed that neural induction also requires FGF signaling [136] and that FGF4 activates Ca^{2+} channels required for neural gene expression [137]. BMP-antagonists such as Noggin trigger intracellular Ca^{2+} release [46], and high Ca^{2+} levels inhibit BMP signaling and simultaneously activate the FGF/Erk signaling pathway [138]. Critically, the presence of Ca^{2+} signaling is required for cells to become neural tissue; in the absence of Ca^{2+} , cells adopt an ectodermal fate [139].

Although Ca^{2+} plays a role in neuralizing tissue, it is unclear whether Ca^{2+} promotes proliferation of neuroectoderm, fosters differentiation, or both [140]. The role of Ca^{2+} in cell cycle is clear. Ca^{2+} is required in all growth and division stages of the cell cycle, encouraging cyclin D1/CDK4 accumulation in early G1, CDK2 activation in G1/S, and CDC2 activity in G2/M (reviewed in [141]). Proliferating fibroblast cells exposed to low Ca^{2+} media arrest in G1 and do not synthesize DNA [142]. Proliferation can be restored in these cells by the addition of Ca^{2+} [142]. The proliferative ventricular zone of the neocortex is reliant on ATP-dependent intracellular Ca^{2+} waves [143]. When Ca^{2+} waves were inhibited with an ATP receptor antagonist, cells failed to enter S phase, as indicated by reduced BrdU staining ([143], reviewed in [144]). Loss of

L-type Ca^{2+} channels, which are differentially expressed in ectodermal tissues during early development [145], causes the down-regulation of *Zic3* and *Geminin* [129], two genes that are associated with the immature, proliferative phase of neurogenesis [57]. Much needs to be learned about other regulators of Ca^{2+} signaling, and which signaling pathway components that control proliferation/differentiation switches are sensitive to Ca^{2+} influx. For example, it has been two decades since Ca^{2+} release during neural induction was shown to increase protein kinase C and cyclic AMP activity, two pathways that are relatively disconnected from BMP and FGF signaling [146–149]. Curiously, this result has not been followed up despite its interest to the field [150].

Members of the Id (Inhibitor of DNA-binding/differentiation) family are helix–loop–helix proteins that inhibit the ability of bHLH proteins to homo- or heterodimerize and bind to DNA [151, 152]; they foster proliferation, in most (but not all) biological systems. $\text{Id1}^{-/-}\text{Id3}^{-/-}$ mouse embryos exhibit premature neurogenesis characterized by ectopic and early onset of expression of neurogenic bHLH proteins, such as MATH1/2/3 and NeuroD1 [153]. Id3 promotes proliferation of neural crest precursors in *Xenopus* [154]. Loss of Id4 compromises the proliferative capacity of ventricular zone stem cells in the mammalian cortex [155]. Id proteins are intrinsically linked to the cell cycle in neurogenesis. Id2 inhibits bHLH factor E47 [156], which prevents heterodimerization of E47 with NeuroD1 [157]. An important downstream target of E47 is the CIK $p57^{\text{Kip2}}$; hence, Id2 effectively down-regulates $p57^{\text{Kip2}}$ via E47 inhibition, thus promoting proliferation in neuroblastoma cells [156]. Activation of the anaphase promoting complex with *Cdh1* coactivator (APC^{Cdh1}) by differentiation signals (such as RA [158]) causes Id2 to be targeted for degradation, thus promoting neuronal differentiation [159]. When *Cdh1* is ablated in mice, increased proliferation in neurospheres and stabilization of substrates such as Geminin is observed [160]. Id1 also antagonizes a different CIK, $p16^{\text{Ink4a}}$ [161], which is found specifically in adult nervous tissue [162]. Taken together, these data indicate that neurogenic transcription factors interact specifically with the cell cycle machinery to modulate proliferation during neurogenesis.

ETS proteins are nuclear targets for extracellular signaling pathways [163] and are modified by mitogen-activated protein kinases (MAPK), integrins, or Ca^{2+} /calmodulin-dependent protein kinases, often downstream of growth factor pathways [163, 164]. Members of the Ets family of transcriptional activators, such as Ets1, Ets2, Elk1 and repressors, such as Ets2 Repressor Factor (ERF) and Ets3, are important cell cycle regulators; their function is tightly regulated by MAPK-mediated phosphorylation. The phosphorylation state of ERF varies at different points

in the cell cycle and this affects ERF subcellular localization. ERF shuttles between the nucleus, where it functions as a repressor, and the cytoplasm where it is inactive [165]. Loss of ERF results in the complete depletion of primary neurons in *Xenopus* embryos [22]. Nuclear localization of ERF occurs in cells arrested in G0 or G1 [165]. Growth factor or serum stimulation of proliferation causes ERK to phosphorylate ERF, which leads to its export from the nucleus [165]. Phosphate mutant ERF proteins cannot be exported and cause cell cycle arrest in the G0/G1 phase [165] and increases the number of *Xenopus* primary neurons [22]. Thus, ERF is critical for negatively regulating transcription factors required for cell cycle re-entry from G0 or quite possibly, elongation of G1 (unpublished data from [166]), which is associated with neuronal differentiation [101]. The direct targets of ERF repression in neurogenesis are currently unknown. However, since Myc has been identified as an ERF target in fibroblasts [167], it is likely that ERF would also repress n-Myc, a gene that is functionally interchangeable with c-Myc [168]. n-Myc promotes expansion of neural progenitor populations, and would be a good candidate to be repressed by ERF to foster differentiation [169].

Many more cell cycle control genes that regulate the differentiation of neural progenitors have yet to be identified. Furthermore, which cell cycle genes are downstream mediators of known differentiation cues remain to be deciphered. Regulators of cell cycle progression during G0 and G1 phase and the G0/G1 transition are likely to be key determinants of the proliferation-differentiation decision. However, it is still controversial whether cells make that decision from G1, or if cells are simply born in G0 due to asymmetrical factors they inherited, or the niche in which they are residing. Various events during the cell cycle such as chromatin remodeling, the opposing effect of cyclin-CDK and CIKs, and the phosphorylation and nuclear shuttling of Ets and Ets repressors form a network that controls when and where neural progenitors commit to differentiate.

Downstream effectors of retinoic acid signaling related to neurogenesis

Throughout neurogenesis, RA is readily available due to the presence of retinaldehyde dehydrogenase 2 (ALDH1A2), which synthesizes RA in the paraxial mesoderm of the developing embryo. RA then diffuses to the neural plate and spinal cord to promote the differentiation of neural progenitors [23]. Due to the availability of RA, and known action of the RARs, most of the direct gene targets of RAR during neurogenesis are expected to be transcriptionally up-regulated; although, the possible recruitment of ligand-dependent transcriptional co-

repressors cannot be completely excluded [170]. Very few direct targets of RA that are definitively involved in the neural proliferation-differentiation switch have been identified. The known direct RAR target, *HoxA1*, [171, 172], is required for the differentiation of embryonic stem (ES) cells into neurons [173]. *HoxA1*-null ES cells are refractory to treatment with RA as measured by reduced expression of post-mitotic neuron markers (e.g., β -tubulin III, *Nestin*); RA sensitivity can be restored by rescue with *HoxA1* cDNA [173]. *Btg2* is also a putative direct target of RAR [174] and is induced by RA in neurula-stage embryos [175, 176] and in various cell lines [174, 177]. *Btg2* decreases arginine methylation and lysine acetylation of histone H4 at RAR target genes, thus increasing the transcriptional activity of RAR [177]. *Btg2* is expressed in differentiating neuroblasts [178] and promotes neuronal differentiation in PC12 cells [179]. Loss of *Btg2* increases proliferation in the neural plate of *Xenopus* embryos [180], likely via repression of Cyclin D1 transcription [181].

Evidence from a variety of cell culture systems shows that RA directly and indirectly regulates the expression of many other genes, in addition to *Btg2*, that facilitate cell cycle exit and differentiation [182–185]. Considering that RAR activation promotes differentiation at the expense of proliferation, the most likely downstream effectors of RAR are inhibitors of the cell cycle. We previously showed that RA-induced ETS repressors are key components of the proliferation-differentiation switch during primary neurogenesis, in vivo [22]. ERF and ETV3 inhibit proliferative signals by displacing activating ETS proteins from promoters of cell cycle control genes while recruiting co-repressor complexes to facilitate cell cycle arrest [186, 187]. ETV3 was identified as an anti-proliferative factor induced during macrophage differentiation [186, 188] and neuronal differentiation [22]. ERF mediates the switch between proliferation and differentiation in macrophages, fibroblasts, extraembryonic ectoderm, and neuroectoderm [22, 167, 187, 189]. Importantly, both *Erf* and *Etv3* are upregulated by RAR agonists, down-regulated by RAR antagonists, and knockdown of ERF or ETV3 results in paralysis, loss of primary neurons and increased proliferation of undifferentiated neural progenitors. Thus, these Ets-repressors are key effectors that inhibit neural progenitor identity and promote differentiation.

Multiple genomics-based studies have elucidated some genes that respond to RA under a variety of differentiation conditions [175, 176, 190–196]. A subset of the genes identified in these analyses will be candidate neurogenic genes regulated by RAR. The pro-neural gene *Ascl1* (*Mash1*), a bHLH transcription factor and activator of Notch signaling, is an interesting downstream effector because *Ascl1* regulates both proliferation and differentiation in a temporally and spatially restricted manner [197].

Ascl1 promotes positive cell cycle regulators in the proliferating ventricular zone of the cortex, but later fosters differentiation in the post-mitotic cortical plate [197]. It is unknown whether there are inherent temporal and spatial differences in RAR signaling in the developing cortex, but RAR is known to create graded, spatially restricted expression of *Ascl1* in other systems. Low *Ascl1* expression is observed in the presence of RA in ventral spinal cord progenitors; high *Ascl1* is observed in the absence of RA in hindbrain serotonergic progenitors [198]. *Numb*, another gene in the Notch pathway, is also a potentially intriguing downstream effector of RA. *Numb* homologs were recently characterized in *Xenopus*—knockdown of *Numb-like* causes the complete loss of primary neurons, expansion of neural progenitor markers, and increased proliferation [199]. *Numb* can promote proliferation or differentiation, depending on which isoform is expressed [200]. A sharp change in *Numb* isoform expression was observed in P19 embryonal carcinoma cells when neuronal differentiation was stimulated by RA [201]. The molecular mechanism of *Numb* alternative splicing remains an open question, although RA-induced differentiation alters splicing machinery in P19 cells [202] and in SH-SY5Y neuroblastoma cells [203].

Other potential downstream effectors of RA include *ATP7A*, *Elongin A*, *Reelin*, and *Prdm12*. RAR β 2 induces the expression of *ATP7A*, a Golgi-associated protein that removes copper from cells [204]. Knock down of RAR β 2 inhibits expression of *ATP7A*, reducing copper efflux. Copper levels are apparently critical for the response of neuroblastoma cells to RA because copper supplementation induced proliferation, and copper chelation promoted differentiation [204]. *Elongin A* is an elongation factor that is essential for neuronal differentiation, in vivo [205]. *Elongin A*^{-/-} embryos have widespread CNS defects, and ES cells derived from these embryos fail to differentiate into neurons in response to RA treatment [205]. The hypothesis is that *Elongin A* improves the processivity of RNA Polymerase II on genes that are upregulated by RA [205]. Increased RNAPII occupancy was observed on *Neurogenin1/2* and *HoxA7* genes in response to RA in *Elongin A*^{+/+} embryonic stem cells; however, this was not observed in *Elongin A*^{-/-} cells [205]. *Reelin* is an extracellular matrix glycoprotein that regulates the number of newborn neurons during development [206]. De novo neurogenesis in regions of the adult brain was decreased in *Reelin*-mutant mice [206]. RA increases occupancy of *Sp1* and *Pax3* promoters, and concomitant demethylation at the *Reelin* promoter in NT2 cells [207, 208]. In summary, some of the important players downstream of RA have been identified, but many of the detailed molecular interactions required for the proliferation of neural progenitors and their differentiation into neurons remain obscure.

Differentiation therapy for cancer

RA has been known to inhibit growth of many tumor-cell lines derived from cancers of different origin (e.g., neuroblastomas, adenocarcinomas, lymphomas, sarcomas, melanomas) for at least 40 years [209]. Neuroblastoma cell lines were commonly used to demonstrate the differentiation and anti-tumorigenic potential of RA. LA-N-1/2/5, CHP-134, KA [210, 211], SH-SY5Y [212], Neuro-2a [213], SK-N-BE2 [214], IMR-32 [215], SMS-KCNR [216], and D283 [217] can all be differentiated by retinoids into cells expressing neuronal markers and exhibiting neurite morphology. Although many cell lines can be differentiated in response to RA, the clinical response to RA treatment is variable. Neuroblastomas represent 11 % of all pediatric cancers [218]. The potential for neuroblastomas to be differentiated is so important that pathological classifications have been created to assess the degree of tumor differentiation—the higher the differentiation state, the better the prognosis [219].

The molecular mechanisms underlying RA-stimulated differentiation in neuroblastomas have not been resolved, nor is the ability of these tumors to become RA resistant completely understood. Some evidence indicates that RARs regulate the expression of microRNAs (miRNAs) that support neurite outgrowth and decrease cellular motility (e.g., invasion and metastasis) and proliferation in neuroblastoma cells (reviewed in [220]). miRNA profiles can predict survival of patients with neuroblastoma, therefore, making targeting miRNAs with antagomirs (oligonucleotides that block miRNA activity) a promising therapy [221]. In addition to altering miRNA expression, RA can induce genome-wide changes in DNA methylation by increasing expression of DNA methyltransferases and concomitant hypomethylation of promoters during neuroblastoma differentiation [222]. These changes in miRNA and DNA methylation alter the epigenetic landscape and ultimately affect the expression of oncogenes and tumor-suppressor genes. For example, microarray data demonstrate that expression of tumor-suppressors such as *Erf* and *Etv3* (see section above) are down-regulated in human medulloblastoma (a type of neuroblastoma) [223–225]. Whether this results from increased methylation of these genes, or if treatment with RA would up-regulate *Erf* and *Etv3* to accelerate differentiation in human neuroblastoma tissue is an intriguing, open question.

Another possible mechanism to explain the success (or lack of success) of tumor differentiation involves RAR coregulators. PRAME is a human tumor antigen that is overexpressed in a variety of cancers and is a prognostic indicator for poor survival in neuroblastomas [226]. PRAME functions as a dominant repressor of RAR signaling that renders cancer cells refractory to RA treatment

[227]. Furthermore, a synthetic lethal screen recently found that stimulating differentiation of neuroblastoma cells is dependent on the transcription factor, ZNF423, a ligand-independent, coactivator of RAR signaling [228, 229]. HDAC inhibitors increase RA sensitivity by promoting dissociation of repressive complexes from RAR, thus, accelerating the differentiation process [230, 231]. Taken together, these studies indicate that the presence or absence of RAR-modulators, such as ZNF423 and PRAME, in tumor cells is critically important for sensitivity of cells to RA differentiation therapy and disease outcome [227, 228].

The identification of neural stem cells (NSCs) [232–234] and CNS stem cells [235, 236] has expanded the possible applications of RA in differentiating tumors of neural origin, particularly in aggressive brain tumors such as glioma, meningioma, and neuroma. It is currently unknown whether most brain tumors originate from mutated NSCs within the perivascular niche [237, 238] or if normal cells acquire mutations that cause their dedifferentiation into immature, carcinogenic neural progenitors [239]. Tumorigenesis could take a hierarchical or linear pathway from cancer stem cells to malignant tumor cells or could result from normal tissue losing differentiation markers (e.g., β -Tubulin) and gaining proliferation markers (e.g., *Sox2*, *Nestin*) (reviewed in [240]). Within the last few years, dedifferentiation as a mode of action in tumorigenesis has been re-evaluated and re-popularized in a variety of cancers including intestinal [241, 242], respiratory [243], breast [244], and brain [239, 245]. Molecular evidence from *Drosophila* revealed that dedifferentiation is associated with the loss of a neural-specific zinc-finger protein Lola-N that normally functions to repress cell cycle genes like *cdc25* in post-mitotic neurons [245]. Loss of *lola* results in brain tumors, and *lola* mutant neurons express neuroblast genes and proliferate in regions of the brain where proliferation usually does not occur [245]. Similar mechanisms might be at work in human tumors.

Considering this renewed interest in dedifferentiation, one might expect RA to play an important role in the treatment of brain tumors. RA was once a prospective treatment for malignant glioma [246–249], but has not proved to be an effective treatment, mostly due to side effects and resistance. There is no doubt that RA is successful in cell culture models of gliomas. In glioblastoma progenitors [250], RA quickly induces cell cycle arrest, inhibiting growth and decreasing clonogenic capacity [251]. RA down-regulates *CD133*, *Msi-1*, *Nestin* and *Sox-2* while increasing differentiation markers in these cells [251]. However, retinoid signaling is more complex in human gliomas, in vivo, and resistance and side effects are common. One possible hypothesis for resistance is that RA can be channeled to a pro-proliferative, oncogenic pathway depending on the relative abundance of the RA-

transporting proteins CRABP2 and FABP5 (reviewed in [252]). In high-grade, undifferentiated, metastasized glioma, CRABP2 is down-regulated and FABP5 is up-regulated [253, 254], which may divert RA towards the PPAR β/δ pathway (promoting cell survival) and away from RARs (which promote differentiation) [255, 256]. This hypothesis is intriguing, but much more research is needed to test it.

A new differentiation therapy for gliomas using IDH1 (isocitrate dehydrogenase 1) inhibitors [257, 258] has provided another link between retinoid signaling and differentiation. IDH1 mutant tumors produce 2-hydroxyglutarate which is associated with genome-wide hypermethylation of a select group of cancer genes which are reproducible and recognizable as a “glioma methylome” [259, 260]. Intriguingly, IDH1 inhibitor therapy absolutely requires retinoid signaling. All IDH1-mutant tumors have retinol binding protein 1 (RBP1) promoter hypermethylation, and decreased levels of RBP1 [261]. Decreased RBP1 ultimately implies that RA bioavailability is reduced, and thus tumors cannot differentiate. RBP1 hypermethylation serves as a unique biomarker of glioma, and might correlate with improved sensitivity to RA differentiation therapy [261]. This result has immediately produced a pre-clinical trial whereby RA has been repurposed in the treatment of IDH-mutant tumors [262].

Summary and future directions

As described above, it is now well-established that the timing of primary neuron appearance and the number of primary neurons produced is regulated by the levels of RA signaling during embryonic development [18–21]. RA acts in opposition to growth factor signaling to halt the proliferation of neural progenitors and stimulate neuronal differentiation. The effects of RA on primary neurogenesis are at least partly mediated by induction of Ets repressors that act at mid- to late gastrula stages to induce cell cycle exit of neuronal progenitors and their differentiation into primary neurons [22]. Although much is known about neuronal differentiation, we still know relatively little about the molecular mechanisms through which RA and its receptors regulate neuronal differentiation and many questions remain to be answered. Which receptors are the primary players in neurogenesis? Knockdown or antagonism of either RAR α or RAR γ blocks primary neurogenesis, suggesting that both may be required for primary neurogenesis [22]. Do these receptors act independently, or is one required for expression or maintenance of the other? While it appears that cell cycle genes are the most likely targets for RAR, it is unclear which of these are critical and whether RARs act indirectly as has been suggested [22], or if RARs recruit ligand-dependent

transcriptional repressors to directly repress expression of cell-cycle genes required for proliferation. Some candidates for downstream effectors of RA signaling can be identified from the literature (see above), but only whole genome approaches are likely to fully elucidate the RA-regulated gene network functional in neurogenesis. The rapid increase in the quality of the available databases from *Xenopus* (*laevis* and *tropicalis*) will facilitate the study of these important questions, *in vivo*.

While a role for RA signaling in primary neurogenesis in anamniote embryos has been demonstrated convincingly, much less is known about its potential roles in neuronal differentiation in amniote embryos. Is RA required for the development of “predecessor neurons” that may correspond to primary neurons, or is this process independent of RA? Apparently *bona fide* RARs have been identified from mollusks and other invertebrates—what is their function in neurogenesis? Can a role for RA in neuronal differentiation be demonstrated in the invertebrates that have apparent RARs, or is the situation more like that in *Drosophila* where neurogenesis does not require RA? Considering that *Oikopleura* has some components of RA signaling (*RXRs*, *Adh3* but not *RARs* or *CYP26*), is it possible that RXR signaling plays an important role in neurogenesis when RARs are absent? Or does RXR play a more fundamental role in neurogenesis of both vertebrates and invertebrates that has, so far, remained unknown?

Although RA was first identified as a differentiation agent that inhibited the growth of numerous tumor-derived cell lines in the 1970s and 1980s, the early promise of RA differentiation therapy was not realized. Recent studies have rekindled interest in RA differentiation therapy for cancers, particularly in aggressive brain tumors such as gliomas. A more complete understanding of how RA regulates cell-cycle exit may provide therapeutic targets for future generations of tumor-selective retinoids. The identification of novel components in RA-regulated signaling pathways in neuronal differentiation may also provide important cancer diagnostic and prognostic markers.

Acknowledgments This study was supported by grants from the National Science Foundation (IOS-0719576, IOS-1147236) to B.B.

References

- Semba RD (2012) On the ‘discovery’ of vitamin A. *Ann Nutr Metab* 61(3):192–198
- Wolf G (1978) A historical note on the mode of administration of vitamin A for the cure of night blindness. *Am J Clin Nutr* 31(2):290–292
- Wald G (1933) Vitamin A in the retina. *Nature* 132:316–317
- Hale F (1933) Pigs born without eyeballs. *J Hered* 24(3):105–106
- Wald G (1968) The molecular basis of visual excitation. *Nature* 219(5156):800–807
- Hart EB, Miller WS, McCollum EV (1916) Further studies on the nutritive deficiencies of wheat and grain mixtures and the pathological conditions produced in swine by their use. *J Biol Chem* 25:239–259
- Hughes JS, Lienhardt HF, Aubel CE (1929) Nerve degeneration resulting from avitaminosis A. *J Nutr* 2(2):183–186
- Aberle SBD (1933) Neurological disturbances in rats reared on diets deficient in vitamin A. *J Nutr* 7(4):445–461
- Jones-Villeneuve EM, McBurney MW, Rogers KA, Kalnins VI (1982) Retinoic acid induces embryonal carcinoma cells to differentiate into neurons and glial cells. *J Cell Biol* 94(2):253–262
- Kuff EL, Fewell JW (1980) Induction of neural-like cells and acetylcholinesterase activity in cultures of F9 teratocarcinoma treated with retinoic acid and dibutyl cyclic adenosine monophosphate. *Dev Biol* 77(1):103–115
- Maden M (2007) Retinoic acid in the development, regeneration and maintenance of the nervous system. *Nat Rev Neurosci* 8(10):755–765
- Petkovich M, Brand NJ, Krust A, Chambon P (1987) A human retinoic acid receptor which belongs to the family of nuclear receptors. *Nature* 330(6147):444–450
- Giguere V, Ong ES, Segui P, Evans RM (1987) Identification of a receptor for the morphogen retinoic acid. *Nature* 330(6149):624–629
- Kruyt FA, van der Veer LJ, Mader S, van den Brink CE, Feijen A, Jonk LJ, Kruijer W, van der Saag PT (1992) Retinoic acid resistance of the variant embryonal carcinoma cell line RAC65 is caused by expression of a truncated RAR alpha. *Differentiation* 49(1):27–37
- Pratt MA, Kralova J, McBurney MW (1990) A dominant negative mutation of the alpha retinoic acid receptor gene in a retinoic acid-nonresponsive embryonal carcinoma cell. *Mol Cell Biol* 10(12):6445–6453
- Matsuo T, Thiele CJ (1998) p27Kip1: a key mediator of retinoic acid induced growth arrest in the SMS-KCNR human neuroblastoma cell line. *Oncogene* 16(25):3337–3343
- Sasaki K, Tamura S, Tachibana H, Sugita M, Gao Y, Furuyama J, Kakishita E, Sakai T, Tamaoki T, Hashimoto-Tamaoki T (2000) Expression and role of p27(kip1) in neuronal differentiation of embryonal carcinoma cells. *Brain Res Mol Brain Res* 77(2):209–221
- Franco PG, Paganelli AR, Lopez SL, Carrasco AE (1999) Functional association of retinoic acid and hedgehog signaling in *Xenopus* primary neurogenesis. *Development* 126(19):4257–4265
- Blumberg B, Bolado J Jr, Moreno TA, Kintner C, Evans RM, Papalopulu N (1997) An essential role for retinoid signaling in anteroposterior neural patterning. *Development* 124(2):373–379
- Papalopulu N, Kintner C (1996) A posteriorising factor, retinoic acid, reveals that anteroposterior patterning controls the timing of neuronal differentiation in *Xenopus* neuroectoderm. *Development* 122(11):3409–3418
- Sharpe CR, Goldstone K (1997) Retinoid receptors promote primary neurogenesis in *Xenopus*. *Development* 124(2):515–523
- Janesick A, Abbey R, Chung C, Liu S, Taketani M, Blumberg B (2013) ERF and ETV3L are retinoic acid-inducible repressors required for primary neurogenesis. *Development* 140(15):3095–3106
- Diez del Corral R, Olivera-Martinez I, Goriely A, Gale E, Maden M, Storey K (2003) Opposing FGF and retinoid pathways control ventral neural pattern, neuronal differentiation, and segmentation during body axis extension. *Neuron* 40(1):65–79

24. Maden M, Gale E, Kostetskii I, Zile M (1996) Vitamin A-deficient quail embryos have half a hindbrain and other neural defects. *Curr Biol* 6(4):417–426
25. Maden M (2002) Retinoid signalling in the development of the central nervous system. *Nat Rev Neurosci* 3(11):843–853
26. Rhinn M, Dolle P (2012) Retinoic acid signalling during development. *Development* 139(5):843–858
27. Niederreither K, Dolle P (2008) Retinoic acid in development: towards an integrated view. *Nat Rev Genet* 9(7):541–553
28. Cunningham TJ, Zhao X, Sandell LL, Evans SM, Trainor PA, Duester G (2013) Antagonism between retinoic acid and fibroblast growth factor signaling during limb development. *Cell Rep* 3(5):1503–1511
29. Wills AE, Choi VM, Bennett MJ, Khokha MK, Harland RM (2010) BMP antagonists and FGF signaling contribute to different domains of the neural plate in *Xenopus*. *Dev Biol* 337(2):335–350
30. Dorey K, Amaya E (2010) FGF signalling: diverse roles during early vertebrate embryogenesis. *Development* 137(22):3731–3742
31. Yan B, Neilson KM, Moody SA (2010) Microarray identification of novel downstream targets of FoxD4L1/D5, a critical component of the neural ectodermal transcriptional network. *Dev Dyn* 239(12):3467–3480
32. Lee HC, Tseng WA, Lo FY, Liu TM, Tsai HJ (2009) FoxD5 mediates anterior-posterior polarity through upstream modulator Fgf signaling during zebrafish somitogenesis. *Dev Biol* 336(2):232–245
33. Branney PA, Faas L, Steane SE, Pownall ME, Isaacs HV (2009) Characterisation of the fibroblast growth factor dependent transcriptome in early development. *PLoS One* 4(3):e4951
34. Marchal L, Luxardi G, Thome V, Kodjabachian L (2009) BMP inhibition initiates neural induction via FGF signaling and Zic genes. *Proc Natl Acad Sci USA* 106(41):17437–17442
35. Tropepe V, Li S, Dickinson A, Gamse JT, Sive HL (2006) Identification of a BMP inhibitor-responsive promoter module required for expression of the early neural gene *zic1*. *Dev Biol* 289(2):517–529
36. Rogers CD, Ferzli GS, Casey ES (2011) The response of early neural genes to FGF signaling or inhibition of BMP indicate the absence of a conserved neural induction module. *BMC Dev Biol* 11:74
37. Aruga J, Mikoshiba K (2011) Role of BMP, FGF, calcium signaling, and Zic proteins in vertebrate neuroectodermal differentiation. *Neurochem Res* 36(7):1286–1292
38. Merzdorf CS (2007) Emerging roles for zic genes in early development. *Dev Dyn* 236(4):922–940
39. Rogers CD, Harafuji N, Archer T, Cunningham DD, Casey ES (2009) *Xenopus* Sox3 activates *sox2* and *geminin* and indirectly represses *Xvent2* expression to induce neural progenitor formation at the expense of non-neural ectodermal derivatives. *Mech Dev* 126(1–2):42–55
40. Aruga J, Tohmonda T, Homma S, Mikoshiba K (2002) *Zic1* promotes the expansion of dorsal neural progenitors in spinal cord by inhibiting neuronal differentiation. *Dev Biol* 244(2):329–341
41. Ebert PJ, Timmer JR, Nakada Y, Helms AW, Parab PB, Liu Y, Hunsaker TL, Johnson JE (2003) *Zic1* represses *Math1* expression via interactions with the *Math1* enhancer and modulation of *Math1* autoregulation. *Development* 130(9):1949–1959
42. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, Guenther MG, Kumar RM, Murray HL, Jenner RG, Gifford DK, Melton DA, Jaenisch R, Young RA (2005) Core transcriptional regulatory circuitry in human embryonic stem cells. *Cell* 122(6):947–956
43. Lim LS, Loh YH, Zhang W, Li Y, Chen X, Wang Y, Bakre M, Ng HH, Stanton LW (2007) *Zic3* is required for maintenance of pluripotency in embryonic stem cells. *Mol Biol Cell* 18(4):1348–1358
44. Loh YH, Wu Q, Chew JL, Vega VB, Zhang W, Chen X, Bourque G, George J, Leong B, Liu J, Wong KY, Sung KW, Lee CW, Zhao XD, Chiu KP, Lipovich L, Kuznetsov VA, Robson P, Stanton LW, Wei CL, Ruan Y, Lim B, Ng HH (2006) The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. *Nat Genet* 38(4):431–440
45. Papanayotou C, De Almeida I, Liao P, Oliveira NM, Lu SQ, Kougioumtzidou E, Zhu L, Shaw A, Sheng G, Streit A, Yu D, Wah Soong T, Stern CD (2013) Calfacilitin is a calcium channel modulator essential for initiation of neural plate development. *Nat Commun* 4:1837
46. Moreau M, Leclerc C, Gualandris-Pariset L, Duprat AM (1994) Increased internal Ca^{2+} mediates neural induction in the amphibian embryo. *Proc Natl Acad Sci USA* 91(26):12639–12643
47. Leclerc C, Daguzan C, Nicolas MT, Chabret C, Duprat AM, Moreau M (1997) L-type calcium channel activation controls the in vivo transduction of the neuralizing signal in the amphibian embryos. *Mech Dev* 64(1–2):105–110
48. Leclerc C, Lee M, Webb SE, Moreau M, Miller AL (2003) Calcium transients triggered by planar signals induce the expression of *ZIC3* gene during neural induction in *Xenopus*. *Dev Biol* 261(2):381–390
49. Batut J, Vandel L, Leclerc C, Daguzan C, Moreau M, Neant I (2005) The Ca^{2+} -induced methyltransferase *xPRMT1b* controls neural fate in amphibian embryo. *Proc Natl Acad Sci USA* 102(42):15128–15133
50. Lim JW, Hummert P, Mills JC, Kroll KL (2011) Geminin cooperates with Polycomb to restrain multi-lineage commitment in the early embryo. *Development* 138(1):33–44
51. Spella M, Britz O, Kotantaki P, Lygerou Z, Nishitani H, Ramsay RG, Flordellis C, Guillemot F, Mantamadiotis T, Taraviras S (2007) Licensing regulators Geminin and Cdt1 identify progenitor cells of the mouse CNS in a specific phase of the cell cycle. *Neuroscience* 147(2):373–387
52. Seo S, Herr A, Lim JW, Richardson GA, Richardson H, Kroll KL (2005) Geminin regulates neuronal differentiation by antagonizing Brg1 activity. *Genes Dev* 19(14):1723–1734
53. Brewster R, Lee J, Altaba AR (1998) Gli/Zic factors pattern the neural plate by defining domains of cell differentiation. *Nature* 393(6685):579–583
54. Yan B, Neilson KM, Moody SA (2009) Notch signaling downstream of foxD5 promotes neural ectodermal transcription factors that inhibit neural differentiation. *Dev Dyn* 238(6):1358–1365
55. Moody SA, Klein SL, Karpinski BA, Maynard TM, Lamantia AS (2013) On becoming neural: what the embryo can tell us about differentiating neural stem cells. *Am J Stem Cells* 2(2):74–94
56. Papanayotou C, Mey A, Birot AM, Saka Y, Boast S, Smith JC, Samarut J, Stern CD (2008) A mechanism regulating the onset of Sox2 expression in the embryonic neural plate. *PLoS Biol* 6(1):e2
57. Rogers CD, Moody SA, Casey ES (2009) Neural induction and factors that stabilize a neural fate. *Birth Defects Res C Embryo Today* 87(3):249–262
58. Chalmers AD, Welchman D, Papalopulu N (2002) Intrinsic differences between the superficial and deep layers of the *Xenopus* ectoderm control primary neuronal differentiation. *Dev Cell* 2(2):171–182
59. Sharpe C, Goldstone K (2000) The control of *Xenopus* embryonic primary neurogenesis is mediated by retinoid signalling in the neuroectoderm. *Mech Dev* 91(1–2):69–80

60. Hartenstein V (1989) Early neurogenesis in *Xenopus*: the spatio-temporal pattern of proliferation and cell lineages in the embryonic spinal cord. *Neuron* 3(4):399–411
61. Carrasco AE, Blumberg B (2004) A Critical Role for Retinoid Receptors in Axial Patterning and Neuronal Differentiation. In: Grunz H (ed) *The Vertebrate Organizer*. Springer Science & Business Media, New York, pp 279–298
62. Wullmann MF, Rink E, Vernier P, Schlosser G (2005) Secondary neurogenesis in the brain of the African clawed frog, *Xenopus laevis*, as revealed by PCNA, Delta-1, Neurogenin-related-1, and NeuroD expression. *J Comp Neurol* 489(3):387–402
63. Hevner RF, Zecevic N (2006) Pioneer Neurons and Interneurons in the Developing Subplate: Molecular Markers, Cell Birthdays, and Neurotransmitters. In: Erzurumlu R, Guido W, Molnár Z (eds) *Development and Plasticity in Sensory Thalamus and Cortex*. Springer US, New York, pp 1–18
64. Raper J, Mason C (2010) Cellular strategies of axonal path-finding. *Cold Spring Harb Perspect Biol* 2(9):a001933
65. Bystron I, Rakic P, Molnar Z, Blakemore C (2006) The first neurons of the human cerebral cortex. *Nat Neurosci* 9(7):880–886
66. Hyatt GA, Schmitt EA, Marsh-Armstrong N, McCaffery P, Drager UC, Dowling JE (1996) Retinoic acid establishes ventral retinal characteristics. *Development* 122(1):195–204
67. Diez del Corral R, Morales A (2014) Retinoic Acid Signaling during Early Spinal Cord Development. *J Dev Biol* 2(3):174–197
68. Kudoh T, Wilson SW, Dawid IB (2002) Distinct roles for Fgf, Wnt and retinoic acid in posteriorizing the neural ectoderm. *Development* 129(18):4335–4346
69. Glover JC, Renaud JS, Rijli FM (2006) Retinoic acid and hindbrain patterning. *J Neurobiol* 66(7):705–725
70. Wilson L, Gale E, Chambers D, Maden M (2004) Retinoic acid and the control of dorsoventral patterning in the avian spinal cord. *Dev Biol* 269(2):433–446
71. Kelley MW, Turner JK, Reh TA (1994) Retinoic acid promotes differentiation of photoreceptors in vitro. *Development* 120(8):2091–2102
72. Osakada F, Ikeda H, Mandai M, Wataya T, Watanabe K, Yoshimura N, Akaike A, Sasai Y, Takahashi M (2008) Toward the generation of rod and cone photoreceptors from mouse, monkey and human embryonic stem cells. *Nat Biotechnol* 26(2):215–224
73. Jacobs S, Lie DC, DeCicco KL, Shi Y, DeLuca LM, Gage FH, Evans RM (2006) Retinoic acid is required early during adult neurogenesis in the dentate gyrus. *Proc Natl Acad Sci USA* 103(10):3902–3907
74. Siegenthaler JA, Ashique AM, Zarbalis K, Patterson KP, Hecht JH, Kane MA, Folias AE, Choe Y, May SR, Kume T, Napoli JL, Peterson AS, Pleasure SJ (2009) Retinoic acid from the meninges regulates cortical neuron generation. *Cell* 139(3):597–609
75. McCaffery PJ, Adams J, Maden M, Rosa-Molinari E (2003) Too much of a good thing: retinoic acid as an endogenous regulator of neural differentiation and exogenous teratogen. *Eur J Neurosci* 18(3):457–472
76. Semmler H, Chiodin M, Bailly X, Martinez P, Wanninger A (2010) Steps towards a centralized nervous system in basal bilaterians: insights from neurogenesis of the acoel *Symsagittifera roscoffensis*. *Dev Growth Differ* 52(8):701–713
77. Burnett AL, Diehl NA (1964) The nervous system of *Hydra*. I. Types, distribution and origin of nerve elements. *J Exp Zool* 157:217–226
78. Galliot B, Quiguand M, Ghila L, de Rosa R, Miljkovic-Licina M, Chera S (2009) Origins of neurogenesis, a cnidarian view. *Dev Biol* 332(1):2–24
79. Simmons DK, Pang K, Martindale MQ (2012) Lim homeobox genes in the Ctenophore *Mnemiopsis leidyi*: the evolution of neural cell type specification. *Evodevo* 3(1):2
80. Jager M, Chiori R, Alie A, Dayraud C, Queinnec E, Manuel M (2011) New insights on ctenophore neural anatomy: immunofluorescence study in *Pleurobrachia pileus* (Müller, 1776). *J Exp Zool B Mol Dev Evol* 316B(3):171–187
81. Burkhardt P, Stegmann CM, Cooper B, Kloepper TH, Imig C, Varoqueaux F, Wahl MC, Fasshauer D (2011) Primordial neurosecretory apparatus identified in the choanoflagellate *Monosiga brevicollis*. *Proc Natl Acad Sci USA* 108(37):15264–15269
82. Canestro C, Bassham S, Postlethwait J (2005) Development of the central nervous system in the larvacean *Oikopleura dioica* and the evolution of the chordate brain. *Dev Biol* 285(2):298–315
83. Canestro C, Albalat R, Postlethwait JH (2010) *Oikopleura dioica* alcohol dehydrogenase class 3 provides new insights into the evolution of retinoic acid synthesis in chordates. *Zool J Linn Soc* 172(2):128–133
84. Marletaz F, Holland LZ, Laudet V, Schubert M (2006) Retinoic acid signaling and the evolution of chordates. *Int J Biol Sci* 2(2):38–47
85. Canestro C, Postlethwait JH, Gonzalez-Duarte R, Albalat R (2006) Is retinoic acid genetic machinery a chordate innovation? *Evol Dev* 8(5):394–406
86. Albalat R, Canestro C (2009) Identification of *Aldh1a*, *Cyp26* and *RAR* orthologs in protostomes pushes back the retinoic acid genetic machinery in evolutionary time to the bilaterian ancestor. *Chem Biol Interact* 178(1–3):188–196
87. Castro LF, Lima D, Machado A, Melo C, Hiromori Y, Nishikawa J, Nakanishi T, Reis-Henriques MA, Santos MM (2007) Impossex induction is mediated through the Retinoid × Receptor signalling pathway in the neogastropod *Nucella lapillus*. *Aquat Toxicol* 85(1):57–66
88. Horiguchi T (2006) Masculinization of female gastropod mollusks induced by organotin compounds, focusing on mechanism of actions of tributyltin and triphenyltin for development of imposex. *Environ Sci* 13(2):77–87
89. Horiguchi T, Ohta Y, Nishikawa T, Shiraishi F, Shiraishi H, Morita M (2008) Exposure to 9-cis retinoic acid induces penis and vas deferens development in the female rock shell, *Thais clavigera*. *Cell Biol Toxicol* 24(6):553–562
90. Nishikawa J, Mamiya S, Kanayama T, Nishikawa T, Shiraishi F, Horiguchi T (2004) Involvement of the retinoid × receptor in the development of imposex caused by organotins in gastropods. *Environ Sci Technol* 38(23):6271–6276
91. Campo-Paysaa F, Marletaz F, Laudet V, Schubert M (2008) Retinoic acid signaling in development: tissue-specific functions and evolutionary origins. *Genesis* 46(11):640–656
92. Dmetrichuk JM, Carlone RL, Jones TR, Vesprini ND, Spencer GE (2008) Detection of endogenous retinoids in the molluscan CNS and characterization of the trophic and tropic actions of 9-cis retinoic acid on isolated neurons. *J Neurosci* 28(48):13014–13024
93. Urushitani H, Katsu Y, Ohta Y, Shiraishi H, Iguchi T, Horiguchi T (2013) Cloning and characterization of the retinoic acid receptor-like protein in the rock shell, *Thais clavigera*. *Aquat Toxicol* 142–143:403–413
94. Gutierrez-Mazariegos J, Nadendla EK, Lima D, Pierzchalski K, Jones JW, Kane M, Nishikawa J, Hiromori Y, Nakanishi T, Santos MM, Castro LF, Bourguet W, Schubert M, Laudet V (2014) A mollusk retinoic acid receptor (RAR) ortholog sheds light on the evolution of ligand binding. *Endocrinology* 155(11):4275–4286

95. Urushitani H, Katsu Y, Ohta Y, Shiraishi H, Iguchi T, Horiguchi T (2011) Cloning and characterization of retinoid X receptor (RXR) isoforms in the rock shell, *Thais clavigera*. *Aquat Toxicol* 103(1–2):101–111
96. Markov GV, Laudet V (2011) Origin and evolution of the ligand-binding ability of nuclear receptors. *Mol Cell Endocrinol* 334(1–2):21–30
97. Bridgham JT, Carroll SM, Thornton JW (2006) Evolution of hormone-receptor complexity by molecular exploitation. *Science* 312(5770):97–101
98. Thornton JW, Need E, Crews D (2003) Resurrecting the ancestral steroid receptor: ancient origin of estrogen signaling. *Science* 301(5640):1714–1717
99. Albalat R (2009) The retinoic acid machinery in invertebrates: ancestral elements and vertebrate innovations. *Mol Cell Endocrinol* 313(1–2):23–35
100. Morrison SJ, Kimble J (2006) Asymmetric and symmetric stem-cell divisions in development and cancer. *Nature* 441(7097):1068–1074
101. Salomoni P, Calegari F (2010) Cell cycle control of mammalian neural stem cells: putting a speed limit on G1. *Trends Cell Biol* 20(5):233–243
102. Pardee AB (1989) G1 events and regulation of cell proliferation. *Science* 246(4930):603–608
103. Bertoli C, Skotheim JM, de Bruin RA (2013) Control of cell cycle transcription during G1 and S phases. *Nat Rev Mol Cell Biol* 14(8):518–528
104. Galderisi U, Jori FP, Giordano A (2003) Cell cycle regulation and neural differentiation. *Oncogene* 22(33):5208–5219
105. Herrup K, Yang Y (2007) Cell cycle regulation in the postmitotic neuron: oxymoron or new biology? *Nat Rev Neurosci* 8(5):368–378
106. Trotter KW, Archer TK (2008) The BRG1 transcriptional coregulator. *Nucl Recept Signal* 6:e004
107. Seo S, Richardson GA, Kroll KL (2005) The SWI/SNF chromatin remodeling protein Brg1 is required for vertebrate neurogenesis and mediates transactivation of *Ngn* and *NeuroD*. *Development* 132(1):105–115
108. Ahmed M, Xu J, Xu PX (2012) EYA1 and SIX1 drive the neuronal developmental program in cooperation with the SWI/SNF chromatin-remodeling complex and SOX2 in the mammalian inner ear. *Development* 139(11):1965–1977
109. Lessard J, Wu JI, Ranish JA, Wan M, Winslow MM, Staahl BT, Wu H, Aebersold R, Graef IA, Crabtree GR (2007) An essential switch in subunit composition of a chromatin remodeling complex during neural development. *Neuron* 55(2):201–215
110. Ninkovic J, Steiner-Mezzadri A, Jawerka M, Akinci U, Masserdotti G, Petricca S, Fischer J, von Holst A, Beckers J, Lie CD, Petrik D, Miller E, Tang J, Wu J, Lefebvre V, Demmers J, Eisch A, Metzger D, Crabtree G, Irmeler M, Poot R, Gotz M (2013) The BAF complex interacts with Pax6 in adult neural progenitors to establish a neurogenic cross-regulatory transcriptional network. *Cell Stem Cell* 13(4):403–418
111. Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. *Genes Dev* 13(12):1501–1512
112. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. *Cell* 75(4):805–816
113. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J (1994) Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. *Cell* 78(1):59–66
114. Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, Elledge SJ, Reed SI (1994) p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. *Cell* 76(6):1013–1023
115. Kato JY, Matsuo M, Polyak K, Massague J, Sherr CJ (1994) Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. *Cell* 79(3):487–496
116. Hengst L, Gopfert U, Lashuel HA, Reed SI (1998) Complete inhibition of Cdk/cyclin by one molecule of p21(Cip1). *Genes Dev* 12(24):3882–3888
117. Reynisdottir I, Polyak K, Iavarone A, Massague J (1995) Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. *Genes Dev* 9(15):1831–1845
118. Cunningham JJ, Roussel MF (2001) Cyclin-dependent kinase inhibitors in the development of the central nervous system. *Cell Growth Differ* 12(8):387–396
119. Mitsuhashi T, Aoki Y, Eksioğlu YZ, Takahashi T, Bhidé PG, Reeves SA, Caviness VS Jr (2001) Overexpression of p27Kip1 lengthens the G1 phase in a mouse model that targets inducible gene expression to central nervous system progenitor cells. *Proc Natl Acad Sci USA* 98(11):6435–6440
120. Vernon AE, Devine C, Philpott A (2003) The cdk inhibitor p27Xic1 is required for differentiation of primary neurones in *Xenopus*. *Development* 130(1):85–92
121. Carruthers S, Mason J, Papalopulu N (2003) Depletion of the cell-cycle inhibitor p27(Xic1) impairs neuronal differentiation and increases the number of ElrC(+) progenitor cells in *Xenopus tropicalis*. *Mech Dev* 120(5):607–616
122. Su JY, Rempel RE, Erikson E, Maller JL (1995) Cloning and characterization of the *Xenopus* cyclin-dependent kinase inhibitor p27XIC1. *Proc Natl Acad Sci USA* 92(22):10187–10191
123. Ali F, Hindley C, McDowell G, Deibler R, Jones A, Kirschner M, Guillemot F, Philpott A (2011) Cell cycle-regulated multi-site phosphorylation of Neurogenin 2 coordinates cell cycling with differentiation during neurogenesis. *Development* 138(19):4267–4277
124. Sabherwal N, Thuret R, Lea R, Stanley P, Papalopulu N (2014) aPKC phosphorylates p27Xic1, providing a mechanistic link between apical polarity and cell-cycle control. *Dev Cell* 31(5):559–571
125. Souopgui J, Solter M, Pieler T (2002) XPak3 promotes cell cycle withdrawal during primary neurogenesis in *Xenopus laevis*. *EMBO J* 21(23):6429–6439
126. Barth LG, Barth LJ (1964) Sequential Induction of the Presumptive Epidermis of the *Rana pipiens* gastrula. *Biol Bull* 127(3):413–427
127. Grunz H, Tacke L (1989) Neural differentiation of *Xenopus laevis* ectoderm takes place after disaggregation and delayed reaggregation without inducer. *Cell Differ Dev* 28(3):211–217
128. Saint-Jeannet JP, Huang S, Duprat AM (1990) Modulation of neural commitment by changes in target cell contacts in *Pleurodeles waltl*. *Dev Biol* 141(1):93–103
129. Leclerc C, Rizzo C, Daguzan C, Neant I, Batut J, Auge B, Moreau M (2001) Neural determination in *Xenopus laevis* embryos: control of early neural gene expression by calcium. *J Soc Biol* 195(3):327–337
130. Takata K, Yamamoto KY, Ishii I, Takahashi N (1984) Glycoproteins responsive to the neural-inducing effect of concanavalin A in *Cynops* presumptive ectoderm. *Cell Differ* 14(1):25–31
131. Gualandris L, Rouge P, Duprat AM (1985) Target cell surface glycoconjugates and neural induction in an amphibian. *J Embryol Exp Morphol* 86:39–51
132. Ozato K, Huang L, Ebert JD (1977) Accelerated calcium ion uptake in murine thymocytes induced by concanavalin A. *J Cell Physiol* 93(1):153–160
133. Greenberg DA, Carpenter CL, Messing RO (1987) Lectin-induced enhancement of voltage-dependent calcium flux and

- calcium channel antagonist binding. *J Neurochem* 48(3): 888–894
134. Hemmati-Brivanlou A, Kelly OG, Melton DA (1994) Follistatin, an antagonist of activin, is expressed in the Spemann organizer and displays direct neuralizing activity. *Cell* 77(2):283–295
 135. Hemmati-Brivanlou A, Melton DA (1994) Inhibition of activin receptor signaling promotes neuralization in *Xenopus*. *Cell* 77(2):273–281
 136. Delaune E, Lemaire P, Kodjabachian L (2005) Neural induction in *Xenopus* requires early FGF signalling in addition to BMP inhibition. *Development* 132(2):299–310
 137. Lee KW, Moreau M, Neant I, Bibonne A, Leclerc C (2009) FGF-activated calcium channels control neural gene expression in *Xenopus*. *Biochim Biophys Acta* 1793(6):1033–1040
 138. Lin HH, Bell E, Uwanogho D, Perfect LW, Noristani H, Bates TJ, Snetkov V, Price J, Sun YM (2010) Neuronatin promotes neural lineage in ESCs via Ca^{2+} signaling. *Stem Cells* 28(11):1950–1960
 139. Moreau M, Neant I, Webb SE, Miller AL, Leclerc C (2008) Calcium signalling during neural induction in *Xenopus laevis* embryos. *Philos Trans R Soc Lond B Biol Sci* 363(1495): 1371–1375
 140. Rebellato P (2013) Calcium signaling in neurogenesis: regulation of proliferation, differentiation and migration of neural stem cells. Karolinska Institutet, Stockholm
 141. Kahl CR, Means AR (2003) Regulation of cell cycle progression by calcium/calmodulin-dependent pathways. *Endocr Rev* 24(6):719–736
 142. Boynton AL, Whitfield JF, Isaacs RJ (1976) The different roles of serum and calcium in the control of proliferation of BALB/c 3T3 mouse cells. *In Vitro* 12(2):120–123
 143. Weissman TA, Riquelme PA, Ivic L, Flint AC, Kriegstein AR (2004) Calcium waves propagate through radial glial cells and modulate proliferation in the developing neocortex. *Neuron* 43(5):647–661
 144. Leclerc C, Neant I, Moreau M (2012) The calcium: an early signal that initiates the formation of the nervous system during embryogenesis. *Front Mol Neurosci* 5:3
 145. Drean G, Leclerc C, Duprat AM, Moreau M (1995) Expression of L-type Ca^{2+} channel during early embryogenesis in *Xenopus laevis*. *Int J Dev Biol* 39(6):1027–1032
 146. Otte AP, Kramer IM, Mannesse M, Lambrechts C, Durston AJ (1990) Characterization of protein kinase C in early *Xenopus* embryogenesis. *Development* 110(2):461–470
 147. Otte AP, van Run P, Heideveld M, van Driel R, Durston AJ (1989) Neural induction is mediated by cross-talk between the protein kinase C and cyclic AMP pathways. *Cell* 58(4):641–648
 148. Otte AP, Koster CH, Snoek GT, Durston AJ (1988) Protein kinase C mediates neural induction in *Xenopus laevis*. *Nature* 334(6183):618–620
 149. Otte AP, Moon RT (1992) Protein kinase C isozymes have distinct roles in neural induction and competence in *Xenopus*. *Cell* 68(6):1021–1029
 150. Stern CD (2005) Neural induction: old problem, new findings, yet more questions. *Development* 132(9):2007–2021
 151. Ling F, Kang B, Sun XH (2014) Id proteins: small molecules, mighty regulators. *Curr Top Dev Biol* 110:189–216
 152. Perk J, Iavarone A, Benezra R (2005) Id family of helix-loop-helix proteins in cancer. *Nat Rev Cancer* 5(8):603–614
 153. Lyden D, Young AZ, Zagzag D, Yan W, Gerald W, O'Reilly R, Bader BL, Hynes RO, Zhuang Y, Manova K, Benezra R (1999) Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. *Nature* 401(6754):670–677
 154. Kee Y, Bronner-Fraser M (2005) To proliferate or to die: role of Id3 in cell cycle progression and survival of neural crest progenitors. *Genes Dev* 19(6):744–755
 155. Yun K, Mantani A, Garel S, Rubenstein J, Israel MA (2004) Id4 regulates neural progenitor proliferation and differentiation in vivo. *Development* 131(21):5441–5448
 156. Rothschild G, Zhao X, Iavarone A, Lasorella A (2006) E Proteins and Id2 converge on p57Kip2 to regulate cell cycle in neural cells. *Mol Cell Biol* 26(11):4351–4361
 157. Longo A, Guanga GP, Rose RB (2008) Crystal structure of E47-NeuroD1/beta2 bHLH domain-DNA complex: heterodimer selectivity and DNA recognition. *Biochemistry* 47(1):218–229
 158. Cuende J, Moreno S, Bolanos JP, Almeida A (2008) Retinoic acid downregulates Rae1 leading to APC(Cdh1) activation and neuroblastoma SH-SY5Y differentiation. *Oncogene* 27(23): 3339–3344
 159. Lasorella A, Stegmuller J, Guardavaccaro D, Liu G, Carro MS, Rothschild G, de la Torre-Ubieta L, Pagano M, Bonni A, Iavarone A (2006) Degradation of Id2 by the anaphase-promoting complex couples cell cycle exit and axonal growth. *Nature* 442(7101):471–474
 160. Eguren M, Porlan E, Manchado E, Garcia-Higuera I, Canamero M, Farinas I, Malumbres M (2013) The APC/C cofactor Cdh1 prevents replicative stress and p53-dependent cell death in neural progenitors. *Nat Commun* 4:2880
 161. Ohtani N, Zebedee Z, Huot TJ, Stinson JA, Sugimoto M, Ohashi Y, Sharrocks AD, Peters G, Hara E (2001) Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence. *Nature* 409(6823):1067–1070
 162. Molofsky AV, Slutsky SG, Joseph NM, He S, Pardoll R, Krishnamurthy J, Sharpless NE, Morrison SJ (2006) Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. *Nature* 443(7110):448–452
 163. Sharrocks AD (2001) The ETS-domain transcription factor family. *Nat Rev Mol Cell Biol* 2(11):827–837
 164. Oikawa T, Yamada T (2003) Molecular biology of the Ets family of transcription factors. *Gene* 303:11–34
 165. Le Gallic L, Virgilio L, Cohen P, Biteau B, Mavrothalassitis G (2004) ERF nuclear shuttling, a continuous monitor of Erk activity that links it to cell cycle progression. *Mol Cell Biol* 24(3):1206–1218
 166. Sgouras DN, Athanasiou MA, Beal GJ Jr, Fisher RJ, Blair DG, Mavrothalassitis GJ (1995) ERF: an ETS domain protein with strong transcriptional repressor activity, can suppress ets-associated tumorigenesis and is regulated by phosphorylation during cell cycle and mitogenic stimulation. *EMBO J* 14(19): 4781–4793
 167. Verykokakis M, Papadaki C, Vorgia E, Le Gallic L, Mavrothalassitis G (2007) The RAS-dependent ERF control of cell proliferation and differentiation is mediated by c-Myc repression. *J Biol Chem* 282(41):30285–30294
 168. Malynn BA, de Alboran IM, O'Hagan RC, Bronson R, Davidson L, DePinho RA, Alt FW (2000) N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation. *Genes Dev* 14(11):1390–1399
 169. Knoepfler PS, Cheng PF, Eisenman RN (2002) N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. *Genes Dev* 16(20):2699–2712
 170. White JH, Fernandes I, Mader S, Yang XJ (2004) Corepressor recruitment by agonist-bound nuclear receptors. *Vitam Horm* 68:123–143
 171. Kolm PJ, Sive HL (1995) Regulation of the *Xenopus* labial homeodomain genes, HoxA1 and HoxD1: activation by retinoids and peptide growth factors. *Dev Biol* 167(1):34–49
 172. Langston AW, Thompson JR, Gudas LJ (1997) Retinoic acid-responsive enhancers located 3' of the Hox A and Hox B homeobox gene clusters. Functional analysis. *J Biol Chem* 272(4):2167–2175

173. Martinez-Ceballos E, Gudas LJ (2008) Hoxa1 is required for the retinoic acid-induced differentiation of embryonic stem cells into neurons. *J Neurosci Res* 86(13):2809–2819
174. Donato LJ, Suh JH, Noy N (2007) Suppression of mammary carcinoma cell growth by retinoic acid: the cell cycle control gene Btg2 is a direct target for retinoic acid receptor signaling. *Cancer Res* 67(2):609–615
175. Arima K, Shiotsugu J, Niu R, Khandpur R, Martinez M, Shin Y, Koide T, Cho KW, Kitayama A, Ueno N, Chandraratna RA, Blumberg B (2005) Global analysis of RAR-responsive genes in the *Xenopus* neurula using cDNA microarrays. *Dev Dyn* 232(2):414–431
176. Janesick A, Nguyen TT, Aisaki K, Igarashi K, Kitajima S, Chandraratna RA, Kanno J, Blumberg B (2014) Active repression by RARGamma signaling is required for vertebrate axial elongation. *Development* 141(11):2260–2270
177. Passeri D, Marcucci A, Rizzo G, Billi M, Panigada M, Leonardi L, Tirone F, Grignani F (2006) Btg2 enhances retinoic acid-induced differentiation by modulating histone H4 methylation and acetylation. *Mol Cell Biol* 26(13):5023–5032
178. Iacopetti P, Barsacchi G, Tirone F, Maffei L, Cremisi F (1994) Developmental expression of PC3 gene is correlated with neuronal cell birthday. *Mech Dev* 47(2):127–137
179. el-Ghissassi F, Valsesia-Wittmann S, Falette N, Duriez C, Walden PD, Puisieux A (2002) BTG2/TIS21/PC3 induces neuronal differentiation and prevents apoptosis of terminally differentiated PC12 cells. *Oncogene* 21(44):6772–6778
180. Sugimoto K, Okabayashi K, Sedohara A, Hayata T, Asashima M (2007) The role of XBtg2 in *Xenopus* neural development. *Dev Neurosci* 29(6):468–479
181. Canzoniere D, Farioli-Vecchioli S, Conti F, Ciotti MT, Tata AM, Augusti-Tocco G, Mattei E, Lakshmana MK, Krizhanovsky V, Reeves SA, Giovannoni R, Castano F, Servadio A, Ben-Arie N, Tirone F (2004) Dual control of neurogenesis by PC3 through cell cycle inhibition and induction of Math1. *J Neurosci* 24(13):3355–3369
182. Georgopoulou N, Hurel C, Politis PK, Gaitanou M, Matsas R, Thomaidou D (2006) BM88 is a dual function molecule inducing cell cycle exit and neuronal differentiation of neuroblastoma cells via cyclin D1 down-regulation and retinoblastoma protein hypophosphorylation. *J Biol Chem* 281(44):33606–33620
183. Kosaka C, Sasaguri T, Komiyama Y, Takahashi H (2001) All-trans retinoic acid inhibits vascular smooth muscle cell proliferation targeting multiple genes for cyclins and cyclin-dependent kinases. *Hypertens Res* 24(5):579–588
184. Luo P, Wang A, Payne KJ, Peng H, Wang JG, Parrish YK, Rogerio JW, Triche TJ, He Q, Wu L (2007) Intrinsic retinoic acid receptor alpha-cyclin-dependent kinase-activating kinase signaling involves coordination of the restricted proliferation and granulocytic differentiation of human hematopoietic stem cells. *Stem Cells* 25(10):2628–2637
185. Sueoka N, Lee HY, Walsh GL, Hong WK, Kurie JM (1999) Posttranslational mechanisms contribute to the suppression of specific cyclin:CDK complexes by all-trans retinoic acid in human bronchial epithelial cells. *Cancer Res* 59(15):3838–3844
186. Klappacher GW, Lunyak VV, Sykes DB, Sawka-Verhelle D, Sage J, Brard G, Ngo SD, Gangadharan D, Jacks T, Kamps MP, Rose DW, Rosenfeld MG, Glass CK (2002) An induced Ets repressor complex regulates growth arrest during terminal macrophage differentiation. *Cell* 109(2):169–180
187. Hester KD, Verhelle D, Escoubet-Lozach L, Luna R, Rose DW, Glass CK (2007) Differential repression of c-myc and cdc2 gene expression by ERF and PE-1/METS. *Cell Cycle* 6(13):1594–1604
188. Sawka-Verhelle D, Escoubet-Lozach L, Fong AL, Hester KD, Herzig S, Lebrun P, Glass CK (2004) PE-1/METS, an antiproliferative Ets repressor factor, is induced by CREB-1/CREM-1 during macrophage differentiation. *J Biol Chem* 279(17):17772–17784
189. Papadaki C, Alexiou M, Cecena G, Vervokakis M, Bilitou A, Cross JC, Oshima RG, Mavrothalassitis G (2007) Transcriptional repressor erf determines extraembryonic ectoderm differentiation. *Mol Cell Biol* 27(14):5201–5213
190. Shi Z, Lou M, Zhao Y, Zhang Q, Cui D, Wang K (2013) Effect of all-trans retinoic acid on the differentiation of U87 glioma stem/progenitor cells. *Cell Mol Neurobiol* 33(7):943–951
191. Arisi MF, Starker RA, Addya S, Huang Y, Fernandez SV (2014) All trans-retinoic acid (ATRA) induces re-differentiation of early transformed breast epithelial cells. *Int J Oncol* 44(6):1831–1842
192. Su D, Gudas LJ (2008) Gene expression profiling elucidates a specific role for RARGamma in the retinoic acid-induced differentiation of F9 teratocarcinoma stem cells. *Biochem Pharmacol* 75(5):1129–1160
193. Oliveira E, Casado M, Raldua D, Soares A, Barata C, Pina B (2013) Retinoic acid receptors' expression and function during zebrafish early development. *J Steroid Biochem Mol Biol* 138:143–151
194. Akanuma H, Qin XY, Nagano R, Win-Shwe TT, Imanishi S, Zaha H, Yoshinaga J, Fukuda T, Ohsako S, Sone H (2012) Identification of Stage-Specific Gene Expression Signatures in Response to Retinoic Acid during the Neural Differentiation of Mouse Embryonic Stem Cells. *Front Genet* 3:141
195. Ishibashi T, Usami T, Fujie M, Azumi K, Satoh N, Fujiwara S (2005) Oligonucleotide-based microarray analysis of retinoic acid target genes in the protochordate, *Ciona intestinalis*. *Dev Dyn* 233(4):1571–1578
196. Coyle DE, Li J, Baccei M (2011) Regional differentiation of retinoic acid-induced human pluripotent embryonic carcinoma stem cell neurons. *PLoS One* 6(1):e16174
197. Castro DS, Martynoga B, Parras C, Ramesh V, Pacary E, Johnston C, Drechsel D, Lebel-Potter M, Garcia LG, Hunt C, Dolle D, Bithell A, Ettwiller L, Buckley N, Guillemot F (2011) A novel function of the proneural factor Ascl1 in progenitor proliferation identified by genome-wide characterization of its targets. *Genes Dev* 25(9):930–945
198. Jacob J, Kong J, Moore S, Milton C, Sasai N, Gonzalez-Quevedo R, Terriente J, Imayoshi I, Kageyama R, Wilkinson DG, Novitch BG, Briscoe J (2013) Retinoid acid specifies neuronal identity through graded expression of Ascl1. *Curr Biol* 23(5):412–418
199. Nieber F, Hedderich M, Jahn O, Pieler T, Henningfeld KA (2013) NumbL is essential for *Xenopus* primary neurogenesis. *BMC Dev Biol* 13:36
200. Verdi JM, Bashirullah A, Goldhawk DE, Kubu CJ, Jamali M, Meakin SO, Lipshitz HD (1999) Distinct human NUMB isoforms regulate differentiation vs. proliferation in the neuronal lineage. *Proc Natl Acad Sci USA* 96(18):10472–10476
201. Bani-Yaghoob M, Kubu CJ, Cowling R, Rochira J, Nikopoulos GN, Bellum S, Verdi JM (2007) A switch in numb isoforms is a critical step in cortical development. *Dev Dyn* 236(3):696–705
202. Alam AH, Suzuki H, Tsukahara T (2010) Retinoic acid treatment and cell aggregation independently regulate alternative splicing in P19 cells during neural differentiation. *Cell Biol Int* 34(6):631–643
203. Meseguer S, Mudduluru G, Escamilla JM, Allgayer H, Barrettino D (2011) MicroRNAs-10a and -10b contribute to retinoic acid-induced differentiation of neuroblastoma cells and target the alternative splicing regulatory factor SFRS1 (SF2/ASF). *J Biol Chem* 286(6):4150–4164

204. Bohlken A, Cheung BB, Bell JL, Koach J, Smith S, Sekyere E, Thomas W, Norris M, Haber M, Lovejoy DB, Richardson DR, Marshall GM (2009) ATP7A is a novel target of retinoic acid receptor beta2 in neuroblastoma cells. *Br J Cancer* 100(1):96–105
205. Yasukawa T, Bhatt S, Takeuchi T, Kawauchi J, Takahashi H, Tsutsui A, Muraoka T, Inoue M, Tsuda M, Kitajima S, Conaway RC, Conaway JW, Trainor PA, Aso T (2012) Transcriptional elongation factor elongin A regulates retinoic acid-induced gene expression during neuronal differentiation. *Cell Rep* 2(5):1129–1136
206. Won SJ, Kim SH, Xie L, Wang Y, Mao XO, Jin K, Greenberg DA (2006) Reelin-deficient mice show impaired neurogenesis and increased stroke size. *Exp Neurol* 198(1):250–259
207. Chen Y, Kundakovic M, Agis-Balboa RC, Pinna G, Grayson DR (2007) Induction of the reelin promoter by retinoic acid is mediated by Sp1. *J Neurochem* 103(2):650–665
208. Chen Y, Sharma RP, Costa RH, Costa E, Grayson DR (2002) On the epigenetic regulation of the human reelin promoter. *Nucleic Acids Res* 30(13):2930–2939
209. Lotan R, Nicolson GL (1977) Inhibitory effects of retinoic acid or retinyl acetate on the growth of untransformed, transformed, and tumor cells in vitro. *J Natl Cancer Inst* 59(6):1717–1722
210. Sidell N (1982) Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro. *J Natl Cancer Inst* 68(4):589–596
211. Sidell N, Altman A, Haussler MR, Seeger RC (1983) Effects of retinoic acid (RA) on the growth and phenotypic expression of several human neuroblastoma cell lines. *Exp Cell Res* 148(1):21–30
212. Encinas M, Iglesias M, Liu Y, Wang H, Muhaisen A, Cena V, Gallego C, Comella JX (2000) Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells. *J Neurochem* 75(3):991–1003
213. Wu PY, Lin YC, Chang CL, Lu HT, Chin CH, Hsu TT, Chu D, Sun SH (2009) Functional decreases in P2X7 receptors are associated with retinoic acid-induced neuronal differentiation of Neuro-2a neuroblastoma cells. *Cell Signal* 21(6):881–891
214. Hammerle B, Yanez Y, Palanca S, Canete A, Burks DJ, Castel V, Font de Mora J (2013) Targeting neuroblastoma stem cells with retinoic acid and proteasome inhibitor. *PLoS One* 8(10):e76761
215. Sumantran VN, Brederlau A, Funa K (2003) BMP-6 and retinoic acid synergistically differentiate the IMR-32 human neuroblastoma cells. *Anticancer Res* 23(2B):1297–1303
216. Thiele CJ, Reynolds CP, Israel MA (1985) Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. *Nature* 313(6001):404–406
217. Hallahan AR, Pritchard JI, Chandraratna RA, Ellenbogen RG, Geyer JR, Overland RP, Strand AD, Tapscott SJ, Olson JM (2003) BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. *Nat Med* 9(8):1033–1038
218. Patterson DM, Shohet JM, Kim ES (2011) Preclinical models of pediatric solid tumors (neuroblastoma) and their use in drug discovery. *Curr Protoc Pharmacol*. Chapter 14:Unit 14.17
219. Shimada H, Umehara S, Monobe Y, Hachitanda Y, Nakagawa A, Goto S, Gerbing RB, Stram DO, Lukens JN, Matthay KK (2001) International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. *Cancer* 92(9):2451–2461
220. Stallings RL, Foley NH, Bray IM, Das S, Buckley PG (2011) MicroRNA and DNA methylation alterations mediating retinoic acid induced neuroblastoma cell differentiation. *Semin Cancer Biol* 21(4):283–290
221. Stallings RL (2009) MicroRNA involvement in the pathogenesis of neuroblastoma: potential for microRNA mediated therapeutics. *Curr Pharm Des* 15(4):456–462
222. Das S, Foley N, Bryan K, Watters KM, Bray I, Murphy DM, Buckley PG, Stallings RL (2010) MicroRNA mediates DNA demethylation events triggered by retinoic acid during neuroblastoma cell differentiation. *Cancer Res* 70(20):7874–7881
223. Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang CH, Angelo M, Ladd C, Reich M, Latulippe E, Mesirov JP, Poggio T, Gerald W, Loda M, Lander ES, Golub TR (2001) Multiclass cancer diagnosis using tumor gene expression signatures. *Proc Natl Acad Sci USA* 98(26):15149–15154
224. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Kim JY, Goumnerova LC, Black PM, Lau C, Allen JC, Zagzag D, Olson JM, Curran T, Wetmore C, Biegel JA, Poggio T, Mukherjee S, Rifkin R, Califano A, Stolovitzky G, Louis DN, Mesirov JP, Lander ES, Golub TR (2002) Prediction of central nervous system embryonal tumour outcome based on gene expression. *Nature* 415(6870):436–442
225. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, Varambally S, Ghosh D, Chinnaiyan AM (2007) Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. *Neoplasia* 9(2):166–180
226. Oberthuer A, Hero B, Spitz R, Berthold F, Fischer M (2004) The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. *Clin Cancer Res* 10(13):4307–4313
227. Epping MT, Wang L, Edel MJ, Carlee L, Hernandez M, Bernards R (2005) The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. *Cell* 122(6):835–847
228. Huang S, Laoukili J, Epping MT, Koster J, Holzel M, Westerman BA, Nijkamp W, Hata A, Asgharzadeh S, Seeger RC, Versteeg R, Beijersbergen RL, Bernards R (2009) ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. *Cancer Cell* 15(4):328–340
229. Holzel M, Huang S, Koster J, Ora I, Lakeman A, Caron H, Nijkamp W, Xie J, Callens T, Asgharzadeh S, Seeger RC, Messiaen L, Versteeg R, Bernards R (2010) NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. *Cell* 142(2):218–229
230. Altucci L, Gronemeyer H (2001) The promise of retinoids to fight against cancer. *Nat Rev Cancer* 1(3):181–193
231. Ulrich T (2013) Curing neuroblastoma by making it grow up, vol 2014. Boston Children's Hospital, Boston
232. Temple S (1989) Division and differentiation of isolated CNS blast cells in microculture. *Nature* 340(6233):471–473
233. Reynolds BA, Weiss S (1992) Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. *Science* 255(5052):1707–1710
234. Snyder EY, Deitcher DL, Walsh C, Arnold-Aldea S, Hartwig EA, Cepko CL (1992) Multipotent neural cell lines can engraft and participate in development of mouse cerebellum. *Cell* 68(1):33–51
235. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB (2003) Identification of a cancer stem cell in human brain tumors. *Cancer Res* 63(18):5821–5828
236. Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, Kornblum HI (2003) Cancerous stem cells can arise from pediatric brain tumors. *Proc Natl Acad Sci USA* 100(25):15178–15183

237. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, Frank A, Bayazitov IT, Zakharenko SS, Gajjar A, Davidoff A, Gilbertson RJ (2007) A perivascular niche for brain tumor stem cells. *Cancer Cell* 11(1):69–82
238. Liu C, Sage JC, Miller MR, Verhaak RG, Hippenmeyer S, Vogel H, Foreman O, Bronson RT, Nishiyama A, Luo L, Zong H (2011) Mosaic analysis with double markers reveals tumor cell of origin in glioma. *Cell* 146(2):209–221
239. Friedmann-Morvinski D, Bushong EA, Ke E, Soda Y, Marumoto T, Singer O, Ellisman MH, Verma IM (2012) Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. *Science* 338(6110):1080–1084
240. Friedmann-Morvinski D, Verma IM (2014) Dedifferentiation and reprogramming: origins of cancer stem cells. *EMBO Rep* 15(3):244–253
241. van Es JH, Sato T, van de Wetering M, Lyubimova A, Nee AN, Gregorieff A, Sasaki N, Zeinstra L, van den Born M, Korving J, Martens AC, Barker N, van Oudenaarden A, Clevers H (2012) Dll1 + secretory progenitor cells revert to stem cells upon crypt damage. *Nat Cell Biol* 14(10):1099–1104
242. Schwitalla S, Fingerle AA, Cammareri P, Nebelsiek T, Goktuna SI, Ziegler PK, Canli O, Heijmans J, Huels DJ, Moreaux G, Rupec RA, Gerhard M, Schmid R, Barker N, Clevers H, Lang R, Neumann J, Kirchner T, Taketo MM, van den Brink GR, Sansom OJ, Arkan MC, Greten FR (2013) Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. *Cell* 152(1–2):25–38
243. Tata PR, Mou H, Pardo-Saganta A, Zhao R, Prabhu M, Law BM, Vinarsky V, Cho JL, Breton S, Sahay A, Medoff BD, Rajagopal J (2013) Dedifferentiation of committed epithelial cells into stem cells in vivo. *Nature* 503(7475):218–223
244. Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, Brooks M, Reinhardt F, Su Y, Polyak K, Arendt LM, Kuperwasser C, Bieri B, Weinberg RA (2011) Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. *Proc Natl Acad Sci USA* 108(19):7950–7955
245. Southall TD, Davidson CM, Miller C, Carr A, Brand AH (2014) Dedifferentiation of neurons precedes tumor formation in *Lola* mutants. *Dev Cell* 28(6):685–696
246. Yung WK, Kyritsis AP, Gleason MJ, Levin VA (1996) Treatment of recurrent malignant gliomas with high-dose 13-*cis*-retinoic acid. *Clin Cancer Res* 2(12):1931–1935
247. See SJ, Levin VA, Yung WK, Hess KR, Groves MD (2004) 13-*cis*-retinoic acid in the treatment of recurrent glioblastoma multiforme. *Neuro Oncol* 6(3):253–258
248. Kaba SE, Kyritsis AP, Conrad C, Gleason MJ, Newman R, Levin VA, Yung WK (1997) The treatment of recurrent cerebral gliomas with all-*trans*-retinoic acid (tretinoin). *J Neurooncol* 34(2):145–151
249. Wismeth C, Hau P, Fabel K, Baumgart U, Hirschmann B, Koch H, Jauch T, Grauer O, Drechsel L, Brawanski A, Bogdahn U, Steinbrecher A (2004) Maintenance therapy with 13-*cis* retinoid acid in high-grade glioma at complete response after first-line multimodal therapy—a phase-II study. *J Neurooncol* 68(1):79–86
250. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F, Vescovi A (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. *Cancer Res* 64(19):7011–7021
251. Ying M, Wang S, Sang Y, Sun P, Lal B, Goodwin CR, Guerrero-Cazares H, Quinones-Hinojosa A, Lateral J, Xia S (2011) Regulation of glioblastoma stem cells by retinoic acid: role for Notch pathway inhibition. *Oncogene* 30(31):3454–3467
252. Wolf G (2008) Retinoic acid as cause of cell proliferation or cell growth inhibition depending on activation of one of two different nuclear receptors. *Nutr Rev* 66(1):55–59
253. Campos B, Centner FS, Bermejo JL, Ali R, Dorsch K, Wan F, Felsberg J, Ahmadi R, Grabe N, Reifenberger G, Unterberg A, Burhenne J, Herold-Mende C (2011) Aberrant expression of retinoic acid signaling molecules influences patient survival in astrocytic gliomas. *Am J Pathol* 178(5):1953–1964
254. Barbus S, Tews B, Karra D, Hahn M, Radlwimmer B, Delhomme N, Hartmann C, Felsberg J, Krex D, Schackert G, Martinez R, Reifenberger G, Lichter P (2011) Differential retinoic acid signaling in tumors of long- and short-term glioblastoma survivors. *J Natl Cancer Inst* 103(7):598–606
255. Schug TT, Berry DC, Shaw NS, Travis SN, Noy N (2007) Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. *Cell* 129(4):723–733
256. Schug TT, Berry DC, Toshkov IA, Cheng L, Nikitin AY, Noy N (2008) Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPARbeta/delta to RAR. *Proc Natl Acad Sci USA* 105(21):7546–7551
257. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E, Kunii K, Pedraza A, Schalm S, Silverman L, Miller A, Wang F, Yang H, Chen Y, Kernysky A, Rosenblum MK, Liu W, Biller SA, Su SM, Brennan CW, Chan TA, Graeber TG, Yen KE, Mellinghoff IK (2013) An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. *Science* 340(6132):626–630
258. Garrett-Bakelman FE, Melnick AM (2013) Differentiation therapy for IDH1/2 mutant malignancies. *Cell Res* 23(8):975–977
259. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, Wilson RK, Van Den Berg D, Shen H, Bengtsson H, Neuvial P, Cope LM, Buckley J, Herman JG, Baylin SB, Laird PW, Aldape K (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. *Cancer Cell* 17(5):510–522
260. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AW, Lu C, Ward PS, Thompson CB, Kaufman A, Guryanova O, Levine R, Heguy A, Viale A, Morris LG, Huse JT, Mellinghoff IK, Chan TA (2012) IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. *Nature* 483(7390):479–483
261. Chou AP, Chowdhury R, Li S, Chen W, Kim AJ, Piccioni DE, Selfridge JM, Mody RR, Chang S, Lalezari S, Lin J, Sanchez DE, Wilson RW, Garrett MC, Harry B, Mottahedeh J, Nghiemphu PL, Kornblum HI, Mischel PS, Prins RM, Yong WH, Cloughesy T, Nelson SF, Liao LM, Lai A (2012) Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas. *J Natl Cancer Inst* 104(19):1458–1469
262. Liao L, Cloughesy T, Lai A (2013) Pre-Clinical Studies Investigating the Use of Isotretinoin for the Treatment of IDH1 Mutant Glioma Patients. Accelerate Brain Cancer Cure, Inc., Neuro-Oncology & Neurosurgery, UCLA
263. Lee SY, Lee HS, Moon JS, Kim JI, Park JB, Lee JY, Park MJ, Kim J (2004) Transcriptional regulation of *Zic3* by heterodimeric AP-1(c-Jun/c-Fos) during *Xenopus* development. *Exp Mol Med* 36(5):468–475
264. Yoon J, Kim JH, Lee OJ, Lee SY, Lee SH, Park JB, Lee JY, Kim SC, Kim J (2013) AP-1(c-Jun/FosB) mediates xFoxD5b expression in *Xenopus* early developmental neurogenesis. *Int J Dev Biol* 57(11–12):865–872